

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁶ : C07D 401/12, A61K 31/40, A01N 43/38, C07D 401/06, 209/08, 209/12, 209/42, 213/80</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/36422</p> <p>(43) International Publication Date: 22 July 1999 (22.07.99)</p>
<p>(21) International Application Number: PCT/US99/00810</p> <p>(22) International Filing Date: 14 January 1999 (14.01.99)</p> <p>(30) Priority Data: 60/071,399 14 January 1998 (14.01.98) US 60/097,880 25 August 1998 (25.08.98) US</p> <p>(71) Applicant (for all designated States except US): THE UAB RESEARCH FOUNDATION [US/US]; Suite 1120G, 700 South 20th Street, Birmingham, AL 35294 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): BROUILLETTE, Wayne, J. [US/US]; 328 Kings Crest Lane, Pelham, AL 35124 (US). MUCCIO, Donald [US/US]; 3531 Atdoann Drive, Hoover, AL 35226 (US). JEDRZEJAS, Mark, J. [PL/US]; 1800 Trail Ridge Drive, Birmingham, AL 35124 (US). BROUILLETTE, Christie, G. [US/US]; 328 Kings Crest Lane, Pelham, AL 35124 (US). DEVEDJIEV, Yancho [BG/US]; 890 Old Brook Road, Charlottesville, VA 22901 (US). CRISTOFOLI, Walter [CA/US]; 2115 17th Avenue, South, Birmingham, AL 35205 (US). DELUCAS, Lawrence, J. [US/US]; 2739 Altadena Road, Birmingham, AL 35243 (US). GARCIA, Jose, Gabriel [MX/US]; 1320 18th Avenue,</p>	<p>South, Birmingham, AL 35205 (US). SCHMITT, Laurent [FR/US]; 1813 Shoshone Drive #22, Lafayette, IN 47905 (US).</p> <p>(74) Agents: KATZ, Mitchell, A. et al.; Needle & Rosenberg, P.C., 127 Peachtree Street, N.E., Atlanta, GA 30303 (US).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>	
<p>(54) Title: METHODS OF SYNTHESIZING AND SCREENING INHIBITORS OF BACTERIAL NAD SYNTHETASE ENZYME, COMPOUNDS THEREOF, AND METHODS OF TREATING BACTERIAL AND MICROBIAL INFECTIONS WITH INHIBITORS OF BACTERIAL NAD SYNTHETASE ENZYME</p>		
<p>(57) Abstract</p> <p>The present invention provides methods of synthesizing and screening inhibitors of bacterial NAD synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial NAD synthetase enzyme.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**METHODS OF SYNTHESIZING AND SCREENING INHIBITORS OF
BACTERIAL NAD SYNTHETASE ENZYME, COMPOUNDS THEREOF, AND
METHODS OF TREATING BACTERIAL AND MICROBIAL INFECTIONS
WITH INHIBITORS
OF BACTERIAL NAD SYNTHETASE ENZYME**

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to United States provisional application Serial No. 60/097,880 filed on August 25, 1998 and to 60/071,399 filed on January 14, 1998. The contents of both of these referenced provisional patent applications are herein incorporated by this reference in their entirety.

GOVERNMENT INTEREST STATEMENT

Some research that contributed to the invention herein was supported, in part, by a grant from the United States Department of Defense, Advanced Research Projects Agency.

BACKGROUND OF THE INVENTION

I. Field of the Invention:

The present invention pertains to antibacterial and antimicrobial agents. In particular, the present invention provides methods of synthesizing and screening compounds that are bacterial nicotinamide adenine dinucleotide (NAD) synthetase enzyme inhibitors. The present invention also provides novel compounds that inhibit bacterial NAD synthetase enzyme. The invention also provides libraries of compounds that comprise bacterial NAD synthetase enzyme inhibitors. Further, the present invention provides compounds that exhibit therapeutic activity as antibacterial agents, antimicrobial agents and broad spectrum antibiotics. Still further, the invention provides methods of treating a mammal with bacterial NAD synthetase enzyme inhibitor compounds. The present invention also provides novel disinfecting agents.

II. Background of the Invention:

Drug-resistant infectious bacteria, that is, bacteria that are not killed or inhibited by existing antibacterial and antimicrobial compounds, have become an alarmingly serious worldwide health problem. (E. Ed. Rubenstein, *Science*, **264**, 360 (1994)). In fact, a number of bacterial infections may soon be untreatable unless alternative drug treatments are identified.

Antimicrobial or antibacterial resistance has been recognized since the introduction of penicillin nearly 50 years ago. At that time, penicillin-resistant infections caused by *Staphylococcus aureus* rapidly appeared. Today, hospitals worldwide are facing unprecedented crises from the rapid emergence and dissemination of microbes resistant to one or more antimicrobial and antibacterial agents commonly in use today. As stated in the Fact Sheet on Antimicrobial Resistance of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, several strains of antibiotic-resistant bacteria are now emerging and are becoming a threat to human and animal populations, including those summarized below:

1) Strains of *Staphylococcus aureus* resistant to methicillin and other antibiotics are endemic in hospitals. Infection with methicillin-resistant *S. aureus* (MRSA) strains may also be increasing in non-hospital settings. Vancomycin is the only effective treatment for MRSA infections. A particularly troubling observation is that *S. aureus* strains with reduced susceptibility to vancomycin have emerged recently in Japan and the United States. The emergence of vancomycin-resistant strains would present a serious problem for physicians and patients.

2) Increasing reliance on vancomycin has led to the emergence of vancomycin-resistant *enterococci* (VRE), bacteria that infect wounds, the urinary tract and other sites. Until 1989, such resistance had not been reported in U.S. hospitals. By 1993,

however, more than 10 percent of hospital-acquired *enterococci* infections reported to the Centers for Disease Control ("CDC") were resistant.

3) *Streptococcus pneumoniae* causes thousands of cases of meningitis and pneumonia, as well as 7 million cases of ear infection in the United States each year. Currently, about 30 percent of *S. pneumoniae* isolates are resistant to penicillin, the primary drug used to treat this infection. Many penicillin-resistant strains are also resistant to other antimicrobial or antibacterial drugs.

4) Strains of multi-drug resistant tuberculosis (MDR-TB) have emerged over the last decade and pose a particular threat to people infected with HIV. Drug-resistant strains are as contagious as those that are susceptible to drugs. MDR-TB is more difficult and vastly more expensive to treat, and patients may remain infectious longer due to inadequate treatment. Multi-drug resistant strains of *Mycobacterium tuberculosis* have also emerged in several countries, including the U.S.











5) Diarrheal diseases cause almost 3 million deaths a year, mostly in developing countries, where resistant strains of highly pathogenic bacteria such as *Shigella dysenteriae*, *Campylobacter*, *Vibrio cholerae*, *Escherichia coli* and *Salmonella* are emerging. Furthermore, recent outbreaks of *Salmonella* food poisoning have occurred in the United States. A potentially dangerous "superbug" known as *Salmonella typhimurium*, resistant to ampicillin, sulfa, streptomycin, tetracycline and chloramphenicol, has caused illness in Europe, Canada and the United States.

In addition to its adverse effect on public health, antimicrobial or antibacterial resistance contributes to higher health care costs. Treating resistant infections often requires the use of more expensive or more toxic drugs and can result in longer hospital stays for infected patients. The Institute of Medicine, a part of the National Academy of Sciences, has estimated that the annual cost of treating antibiotic resistant infections in the United States may be as high as \$30 billion.

Given the above, it would be highly desirable to develop novel antibacterial and antimicrobial agents that act by different mechanisms than those agents in use currently. Further, it would be desirable to be able to synthesize such novel compounds. It would also be desirable to develop libraries of compounds that exhibit inhibitory bacterial NAD synthetase activity. Such new agents would be useful to counteract antibiotic resistant strains of bacteria and other types of harmful microbes. It would be even more desirable to develop antibacterial agents that inhibit or block essential bacterial metabolic mechanisms, to result in bacterial death or deactivation, without also effecting the essential metabolic activities of a mammalian host. That is, it would be desirable to develop antibacterial agents that preferentially attack bacteria and other microbes and kill or deactivate the harmful organism without causing any attendant undesirable side effects in a human or animal patient. It would also be desirable to develop methods of rapidly screening potential new antimicrobial and antibacterial agents. It would also be desirable to develop novel disinfecting agents.

SUMMARY OF THE INVENTION








In one aspect, the invention provides a NAD synthetase inhibitor compound of the formula:



WO 99/36422

6


PCT/US99/00810




WO 99/36422

7


PCT/US99/00810




765




766




767




768




769




832




848



849



850










853

WO 99/36422

9


PCT/US99/00810



WO 99/36422


10

PCT/US99/00810




884

886




887

889



891

894




906

909


WO 99/36422

11


PCT/US99/00810




917




921




924




936










939




941




942



or




In a further aspect, the invention provides a bacterial NAD synthetase enzyme inhibitor compound, having Structure 2:



Structure 2

wherein n is an integer of from 1 to 12, $R_1 - R_7$ each, independently, is an H, an unsubstituted or a substituted cyclic or aliphatic group, a branched or an unbranched group, wherein the linker is a cyclic or aliphatic, branched or an unbranched alkyl, alkenyl, or an alkynyl group and wherein the linker may also contain heteroatoms.

In yet another aspect, the invention provides a bacterial NAD synthetase enzyme inhibitor compound, having Structure 4:



Structure 4

wherein X is a C, N, O or S within a monocyclic or bicyclic moiety, A and B represent the respective sites of attachment for the linker, n is an integer of from 1 to 12, $R_1 - R_7$ each,

independently, is an H, an unsubstituted or a substituted cyclic group, or an aliphatic group, or a branched or an unbranched group, wherein the linker is a saturated or unsaturated cyclic group or an aliphatic branched or unbranched alkyl, alkenyl or alkynyl group, and wherein the linker may also contain heteroatoms.

Further, the invention provides a method of treating or preventing a microbial infection in a mammal comprising administering to the mammal a treatment effective or treatment preventive amount of a bacterial NAD synthetase enzyme inhibitor compound. Still further, a method is provided of killing a prokaryote with an amount of prokaryotic NAD synthetase enzyme inhibitor to reduce or eliminate the production of NAD whereby the prokaryote is killed. Moreover, a method is provided of decreasing prokaryotic growth, comprising contacting the prokaryote with an amount of a prokaryotic NAD synthetase enzyme inhibitor effective to reduce or eliminate the production of NAD whereby prokaryotic growth is decreased. Further provided is a disinfectant compound wherein the compound comprises a bacterial NAD synthetase enzyme inhibitor. Still further, the invention provides a method of disinfecting a material contaminated by a microbe, comprising contacting a contaminated material with a bacterial NAD synthetase enzyme inhibitor compound in an amount sufficient to kill or deactivate the microbe.

In yet another aspect, the invention provides a method of making a bacterial NAD synthetase inhibitor compound comprising the steps of: a. alkylating 5-nitroindole with 6-bromohexyl acetate to form a 6-[N-(5-nitroindolyl)] hexyl acetate; b. hydrolyzing the 6-[N-(5-nitroindolyl)] hexyl acetate to form 6-[N-(5-nitroindolyl)]hexan-1-ol; c. esterifying the 6-[N-(5-nitroindolyl)]hexan-1-ol with nicotinic acid to form 6-[N-(5-nitroindolyl)]hexyl nicotinate; and d. N-methylating the 6-[N-(5-nitroindolyl)]hexyl nicotinate.

Further, the invention provides a method of making a bacterial NAD synthetase inhibitor compound comprising the steps of: a. alkylating 5-nitroindole with bromoalkyl acetate wherein the indole alkyl acetate is converted to indole alkyl alcohol; b. reacting the indole alkyl alcohol with the appropriate reagent to form an indole alkyl ester; and c. N-

Moreover, the invention provides a method of making a bacterial NAD synthetase inhibitor compound comprising the steps of: a. reacting indole carboxylic acid with the appropriate reagent to provide an indole carboxylate methyl ester or an indole benzyl carboxylate ester; b. *N*-alkylating the indole carboxylate methyl ester or the indole carboxylate benzyl ester with bromoalkyl acetate; c. reacting the material from step b above with the appropriate reagent to form an indolealkyl alcohol; d. coupling the indolealkyl alcohol with an aromatic amine; and e. reacting the indolealkyl alcohol with the appropriate reagent to convert the methyl or benzyl indolecarboxylate to the respective indole carboxylic acids.

In another aspect, the invention provides a method of making a bacterial NAD synthetase inhibitor compound comprising the steps of: a. brominating an aniline with *N*-bromosuccinimide to form a 2-bromo- R^1 -substituted-aniline or a 2-bromo- R^2 -substituted-aniline; b. reacting the 2-bromo- R^1 -substituted-aniline or the 2-bromo- R^2 -substituted-aniline using a Heck coupling reaction to form an alkyne-substituted aniline; c. reacting the alkyne-substituted aniline using a cyclization reaction to form an indole alcohol; d. quaternizing the indole alcohol with an amine; e. reacting the indole alcohol with methansulfonyl chloride to provide an indole mesylate; and f. reacting the indole mesylate with a carboxylic acid to form an indole ester.

Still further, the invention provides a method of making a bacterial NAD synthetase inhibitor compound comprising the steps of: a. brominating an aniline with *N*-bromosuccinimide to form a 2-bromo- R^1 -substituted-aniline or a 2-bromo- R^2 -substituted-aniline; b. reacting the 2-bromo- R^1 -substituted-aniline or a 2-bromo- R^2 -substituted-aniline using a Heck coupling reaction to form an alkyne-substituted aniline; c. reacting the alkyne-substituted aniline using a cyclization reaction to form an indole alcohol; d. quaternizing the indole alcohol with an amine; e. reacting the indole alcohol with trifluoromethylsulfonic anhydride to provide a triflate; and f. reacting the indole triflate with an amine to form an indole alkylammonium product.

In yet another aspect, the invention provides a method of generating a library comprising at least one bacterial NAD synthetase enzyme inhibitor compound comprising the steps of: a. obtaining the crystal structure of a bacterial NAD synthetase enzyme; b. identifying one or more sites of catalytic activity on the NAD synthetase enzyme; c. identifying the chemical structure of the catalytic sites on the NAD synthetase enzyme; d. selecting one or more active molecules that will demonstrate affinity for at least one of the catalytic sites on the NAD synthetase enzyme; f. synthesizing one or more dimeric compounds comprised of at least one active molecule wherein the active molecule compound are joined by means of n linker compounds and wherein n is an integer of from 1 to 12, and g. screening the one or more compounds for NAD synthetase inhibitor activity.

In a further aspect of the invention herein, a method is provided for the *in vitro* screening a compound for bacterial NAD synthetase enzyme inhibitory activity comprising the steps of: a. preparing a bacterial NAD synthetase enzyme solution from pure bacterial NAD synthetase enzyme mixed with a suitable buffer; b. contacting the bacterial NAD synthetase enzyme solution with a test compound; and c. measuring the rate of the enzyme-catalyzed reaction between the NAD synthetase enzyme and the test compound, wherein the rate of the enzyme catalyzed reaction comprises a measure of bacterial NAD synthetase enzyme inhibitory activity.

Additional advantages of the invention will be set forth in part in the description that follows, and in part will be obvious from the description, or may be learned by practice of the invention. The advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.


DETAILED DESCRIPTION OF THE INVENTION

The present invention may be understood more readily by reference to the following detailed description of preferred embodiments of the invention and the Examples included herein.

Before the present methods, compounds, compositions and apparatuses are disclosed and described it is to be understood that this invention is not limited to the specific synthetic methods described herein. It is to be further understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise.

Ranges may be expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another embodiment.

Throughout this application, where a chemical diagram has a straight line emanating from a chemical structure, such a line represents a CH_3 group. For example, in the following diagram:



o-methylbenzoic acid is represented.

The term "alkyl" as used herein refers to a branched or unbranched saturated hydrocarbon group of 1 to 24 carbon atoms, such as methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *t*-butyl, octyl, decyl, tetradecyl, hexadecyl, eicosyl, tetracosyl and the like. The term "cycloalkyl" intends a cyclic alkyl group of from three to eight, preferably five or six carbon atoms.

The term "alkoxy" as used herein intends an alkyl group bound through a single, terminal ether linkage; that is, an "alkoxy" group may be defined as -OR where R is alkyl as defined above. A "lower alkoxy" group intends an alkoxy group containing from one to six, more preferably from one to four, carbon atoms.

The term "alkylene" as used herein refers to a difunctional saturated branched or unbranched hydrocarbon chain containing from 1 to 24 carbon atoms, and includes, for example, methylene (-CH₂-), ethylene (-CH₂-CH₂-), propylene (-CH₂-CH₂-CH₂-), 2-methylpropylene [-CH₂-CH(CH₃)-CH₂-], hexylene [-(CH₂)₆-] and the like. The term "cycloalkylene" as used herein refers to a cyclic alkylene group, typically a 5- or 6-membered ring.

The term "alkene" as used herein intends a mono-unsaturated or di-unsaturated hydrocarbon group of 2 to 24 carbon atoms. Asymmetric structures such as (AB)C=C(CD) are intended to include both the E and Z isomers. This may be presumed in structural formulae herein wherein an asymmetric alkene is present.

The term "alkynyl" as used herein refers to a branched or unbranched unsaturated hydrocarbon group of 1 to 24 carbon atoms wherein the group has at least one triple bond.

The term "cyclic" as used herein intends a structure that is characterized by one or more closed rings. As further used herein, the cyclic compounds discussed herein may be saturated or unsaturated and may be heterocyclic. By heterocyclic, it is meant a closed-

ring structure, preferably of 5 or 6 members, in which one or more atoms in the ring is an element other than carbon, for example, sulfur, nitrogen, etc.

The term "bicyclic" as used herein intends a structure with two closed rings. As further used herein, the two rings in a bicyclic structure can be the same or different. Either of the rings in a bicyclic structure may be heterocyclic.

By the term "effective amount" of a compound as provided herein is meant a sufficient amount of the compound to provide the desired treatment or preventive effect. As will be pointed out below, the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease that is being treated, the particular compound used, its mode of administration, and the like. Thus, it is not possible to specify an exact "effective amount." However, an appropriate effective amount may be determined by one of ordinary skill in the art using only routine experimentation. It is preferred that the effective amount be essentially non-toxic to the subject, but it is contemplated that some toxicity will be acceptable in some circumstances where higher dosages are required.

By "pharmaceutically acceptable carrier" is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with the compounds of the invention without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.

As used herein, "NAD synthetase enzyme" is defined as the enzyme that catalyzes the final reaction in the biosynthesis of NAD, namely, the transformation of NaAD into NAD. As used herein, the term "catalytic sites" are defined as those portions of the NAD synthetase enzyme that bind to substrates, and cofactors, including nicotinic acid dinucleotide (NaAD), NAD, adenosine triphosphate (ATP), adenosine monophosphate (AMP), pyrophosphate, magnesium and ammonia in bacteria or microbes. The term "receptor site" or "receptor subsite" relates to those portions of the bacterial NAD

synthetase enzyme in which the bacterial NAD synthetase enzyme inhibitors disclosed herein are believed to bind. For the purposes of this disclosure, the terms "catalytic site," "receptor site" and "receptor subsite" may be used interchangeably.

As used herein, the terms "library" and "library of compounds" denote an intentionally created collection of differing compounds which can be prepared by the synthetic means provided herein or generated otherwise using synthetic methods utilized in the art. The library can be screened for biological activity in any variety of methods, such as those disclosed below herein, as well as other methods useful for assessing the biological activity of chemical compounds. One of skill in the art will recognize that the means utilized to generate the libraries herein comprise generally combinatorial chemical methods such as those described in *Gallop, et al*, "Applications of Combinatorial Techniques to Drug Discovery," "Part 1 Background and Peptide Combinatorial Libraries," and "Part 2: Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions," *J. Med. Chem.*, Vol. 37(1994) pp. 1233 and 1385. As used herein, the terms "combinatorial chemistry" or "combinatorial methods" are defined as the systematic and repetitive, covalent connection of a set of different "building blocks" of varying structure, such as the active molecules disclosed herein, to provide a large array of diverse molecular entities. As contemplated herein, the large array of diverse molecular entities together form the libraries of compounds of the invention.


As used herein, the term "antibacterial compound" denotes a material that kills or deactivates bacteria or microbes so as to reduce or eliminate the harmful effects of the bacteria on a subject or in a system. Such materials are also known in the art as "bacteriostatic agents" or "bacteriocidal agents." The bacteria so effected can be gram positive, gram negative or a combination thereof. The terms "antimicrobial compound" and "broad spectrum antibiotic" denote a material that kills or deactivates a wide variety of microbes, including, but not limited to, one of more of, gram positive or gram negative bacteria, *Staphylococcus aureus*, *Streptococcus pyogenes*, *Streptococcus viridans*, *Enterococcus*, *anaerobic Streptococcus*, *Pneumococcus*, *Gonococcus*, *Meningococcus*, *Mima*, *Bacillus anthracis*, *C. diphtheriae*, *List. monocytogenes*, *Streptobacillus*

monohiliformis, *Erysipelothrix insidiosa*, *E. coli*, *A. aerogenes*, *A. faecalis*, *Proteus mirabilis*, *Pseudomonas aeruginosa*, *K. pneumoniae*, *Salmonella*, *Shigella*, *H. influenzae*, *H. ducreyi*, *Brucella*, *Past. pestis*, *Past. tularensis*, *Past. multocida*, *V. comma*, *Actinobacillus mallei*, *Pseud. pseudomallei*, *Cl. tetani*, *Bacteroides*, *Fusobacterium fusiforme*, *M. tuberculosis*, atypical mycobacteria, *Actinomyces israelii*, *Nocardia*, *T. pallidum*, *T. perne*, *Borrelia recurrentis*, *Peptospira*, *Rickettsia*, and *Mycoplasma pneumoniae*.

In accordance with the desirability for developing improved antibacterial and antimicrobial agents, with the invention herein novel compounds have been identified that inhibit bacterial NAD synthetase enzymatic activity. Such activity translates into effectiveness as bacteriocidal agents, as well as effectiveness a broad spectrum antibiotic materials. Novel compounds have been developed that inhibit a previously unrecognized target in prokaryotic organisms, such as bacteria, to block essential biological function and thereby cause bacterial death or deactivation of bacteria or other microbes. Specifically, the invention herein has identified an enzyme found in both gram positive and gram negative bacteria, NAD synthetase enzyme, which can be utilized as a target for drug design to provide protection from and/or treatment for bacterial and other microbial infections.

The NAD synthetase enzyme catalyzes the final step in the biosynthesis of nicotinamide adenine dinucleotide (NAD). Bacterial NAD synthetase is an ammonia-dependent amidotransferase belonging to a family of "N-type" ATP pyrophosphatases; this family also includes asparagine synthetase and argininosuccinate synthetase. NAD synthetase enzyme catalyzes the last step in both the *de novo* and salvage pathways for NAD⁺ biosynthesis, which involves the transfer of ammonia to the carboxylate of nicotinic acid adenine dinucleotide (NaAD) in the presence of ATP and Mg²⁺. The overall reaction is illustrated in Scheme 1.

SCHEME 1:




Unlike eukaryotic NAD synthetase *i.e.*, that found in mammals and yeast, which can utilize glutamine as a source of nitrogen, prokaryotic NAD synthetase in bacteria utilizes ammonia as the sole nitrogen source. Through x-ray crystallography and other methods, the invention has identified marked differences in the structures of eukaryotic and prokaryotic forms of the NAD synthetase enzyme. For example, *B. subtilis* NAD synthetase enzyme, which in the invention has been crystallized and used in the drug design methodologies herein, is a dimeric material with molecular weight around 60,500. In marked contrast, the eukaryotic form of NAD synthetase found in yeast and mammals is multimeric and has a molecular weight of at least 10 times larger.

By utilizing the significant differences between the eukaryotic and prokaryotic forms of NAD synthetase enzyme, the invention herein provides novel compounds that

can be utilized as antibacterial and antimicrobial agents that specifically target the prokaryotic NAD synthetase enzyme without also effecting a mammalian host. With the invention herein, it has been found that by specifically inhibiting bacterial NAD synthetase enzymatic activity, bacteria can be deprived of the energy necessary to thrive and replicate. Accordingly, through the invention disclosed and claimed herein, antibacterial and antimicrobial drugs have been developed that preferentially attack the bacteria to kill or deactivate it so as to reduce or eliminate its harmful properties, without appreciably affecting mammalian NAD synthetase enzymatic activity at the same dosage. Furthermore, novel methods are provided that allow the rapid screening of compounds for bacterial NAD synthetase enzyme inhibitory activity. Moreover, the invention provides methods of treating microbial infections in a subject.


Without being bound by theory, through chemical analysis and x-ray crystallography methods, characterized at least two separate catalytic subsites on the bacterial NAD synthetase enzyme in which it is possible to bind at least one or more small molecules ("active molecules") have been characterized. These sites are illustrated below by the cartoon in Figure 2.

FIGURE 2: CATALYTIC SITES IN BACTERIAL NAD SYNTHETASE ENZYME



Because of the specific structure of these catalytic sites, it has been determined that it is possible to identify small molecules that will demonstrate affinity for at least one of the sites. Small molecules of the proper configuration, the configuration being determined by the structure of the catalytic site(s), will bind with a receptor site or sites on the bacterial NAD synthetase enzyme, thereby blocking the catalytic activity of the enzyme. Figure 4 illustrates *via* cartoon a bacterial NAD synthetase enzyme in which the catalytic sites are blocked by an example of a compound of the present invention.

FIGURE 4: BACTERIAL NAD SYNTHETASE ENZYME WITH BLOCKED CATALYTIC/RECEPTOR SITES



Under such circumstances, spore-forming bacteria will be unable to undergo germination and outgrowth, and the essential cellular respiratory functions of the vegetative bacteria will be halted, thereby causing cellular death or deactivation, *e.g.*, gram positive and gram negative bacteria and other microbes will be killed or prevented from undergoing growth. Accordingly, the invention has found that compounds that exhibit inhibitory activity against the bacterial NAD synthetase enzyme will also exhibit therapeutic activity as antibacterial and antimicrobial compounds, as well as broad spectrum antibiotic materials.


With the invention herein it has been surprisingly found that it is possible to synthesize novel tethered dimeric compounds that will exhibit activity as bacterial NAD synthetase enzyme inhibitors. By linking one or more active molecules through a linker molecule, one or more ends of the tethered dimer can bind in the respective receptor sites or subsites to thereby render the bacterial NAD synthetase enzyme inactive. When more than one active molecule is used, each active molecule can be the same or different. The

term "active molecules" as used herein refers to small molecules that may be used alone or tethered together through a linker, (tether) fragment to form a tethered dimeric compound.

In the present invention, the active molecules are comprised of substituent groups as hereinafter disclosed that will bind with at least one of the receptor sites in bacterial NAD synthetase enzyme. In the invention herein one or more active molecules are tethered together to form a dimeric molecule that is capable of inhibiting the bacterial NAD synthetase enzyme.

Further, in this invention it has been found that, under some circumstances, different active molecules will be more likely to bind to different locations in the receptor site of a bacterial NAD synthetase enzyme because of the differing chemical make-up of each of these sites. Therefore, in one embodiment, it is beneficial to tether at least two different active molecules to each other wherein each active molecule demonstrates selective affinity for a different subsite in the receptor. Using the tethered dimers herein it is possible to drastically enhance the potency of NAD synthetase enzyme inhibition, as compared to blocking a single site on the bacterial NAD synthetase enzyme. As used herein, the term "selective affinity" means that the active molecule shows enhanced tendency to bind with one subsite with the receptor in the bacterial NAD synthetase enzyme because of a chemical complementarity between the receptor subsite and the active molecule. A tethered dimer compound is illustrated in Scheme 2 below.

SCHEME 2:



In one embodiment, a dimeric inhibitor compound will bind with, for example, the sites of catalytic activity on the bacterial NAD synthetase enzyme, thereby preventing the

production of NAD/NADH by the bacteria. As an additional surprising finding in this invention, it has been determined that by varying the length of the linker molecule, and, accordingly, the distance between the two active molecules, the affinity of the tethered inhibitor compound for the NAD synthetase enzyme will also vary.

In practice of the invention relating to the design of novel NAD synthetase enzyme inhibitor compounds, a software program can be utilized which facilitates the prediction of the binding affinities of molecules to proteins so as to allow identification of commercially available small molecules with the ability to bind to at least one receptor subsite in the bacterial NAD synthetase enzyme. An example of one such computer program is DOCK, available from the Department of Pharmaceutical Chemistry at the University of California, San Francisco. DOCK evaluates the chemical and geometric complementarity between a small molecule and a macromolecular binding site. However, such a program would be useless in the design of a bacterial NAD synthetase enzyme inhibitor in the absence of complete information regarding the enzyme's structure and the chemical makeup of the receptor sites, identified and disclosed fully for the first time herein.

With this invention, the crystal structure of one type of bacterial NAD synthetase enzyme *e.g.*, *B. subtilis* has been for the first time identified fully. The x-ray crystal structure of NAD synthetase enzyme from *B. subtilis* had been reported in the literature. This was accomplished in free form and in complex with ATP and Mg^{+2} at 2.6 and 2.0 Å, respectively. This structure contained the hydrolyzed form of ATP, namely AMP and Ppi, in the ATP binding site and ATP was present in the NaAD binding site. However, the prior art was not able to obtain the structure of the enzyme complex containing NaAD due to technical problems that precluded full identification. Without the structure of the enzyme complex containing NaAD, the structure-based drug design targeted to NAD synthetase enzyme of the present invention could not be developed.

In order to carry out structure-based drug design targeted to bacterial NAD synthetase enzyme, the structure of the enzyme in complex with all substrates, including NaAD has been solved herein. The additional structural information obtained in this

invention for the first time clearly defined the interactions between NaAD and the enzyme, which provided information important for guiding combinatorial library design and inhibitor identification. Schematic drawings of crystal structures of the open and blocked receptor/catalytic sites of *B. subtilis* are set out previously in Figures 2 and 4.

The invention utilizes two approaches reported in the literature (for other biological targets) to help identify lead compounds. (1) Once the structure of a bacterial NAD synthetase catalytic site was identified, the software DOCK (I.D. Kunz *et al.*, **J. Mol. Biol.**, 161, 269-288 (1982)) was utilized to search the Available Chemicals Directory database and computationally score the relative binding affinities for each structure. Based on these results and structural information regarding substrate binding, commercially available compounds were selected for purchase and subsequent enzyme kinetics evaluation. Such database searching strategies in drug discovery are now commonly used by those of skill in the art of drug design. (D.T. Manallack, **Drug Discovery Today**, 1, 231-238 (1996)). (2) Using the results of biological screening for selected commercially available compounds to identify biologically active molecules, the inventors then designed a combinatorial library consisting of "tethered dimers" to rapidly identify more effective inhibitors of NAD synthetase enzyme as antibacterial agents. The use of "tethered dimers" to enhance the binding affinity of two moderately effective small molecule ligands that interact in the same binding site has been previously described in the literature. (S.B. Stucker, P.J. Hejduk, R.P. Meadows, and S.W. Fesik, **Science**, 274, 1531-1534 (1996)). However, this invention involves the first and, therefore, a novel application of database searching coupled with a combinatorial tethered dimer approach that was guided by the structure of and targeted to the bacterial NAD synthetase enzyme.

Examples from the top scoring small molecules as determined by, for example, DOCK, are preferably pre-screened using *in vitro* enzyme assays as further described herein. As a significant aspect of the invention herein, the preferred screening method utilized should allow the rapid screening of large numbers of compounds for inhibitory activity. In a preferred method of the present invention, the small molecule inhibitor candidate for each site that is most promising as an active molecule, as identified by

DOCK (or other programs known to one of skill in the art) and the prescreening method herein, or that were designed based upon the substrate protein complex structure, were synthesized according to the methods disclosed herein below.

In one embodiment, the active molecules are chemically tethered to one another by means of a linker compound. In a further embodiment, the linker comprises one or more CH_2 or other groups, using a variety of tether lengths, preferably 1 to 12 nonhydrogen atoms, more preferably 3 to 10 nonhydrogen atoms, further more preferably 5 to 9 nonhydrogen atoms and, still more preferably, 6 to 9 nonhydrogen atoms.

In another embodiment of the present invention, the novel compounds with preferred structures determined from the methods described above are synthesized by means of rapid, solution phase parallel synthesis of the tethered dimers compounds in a combinatorial fashion. One of skill in the art will recognize such techniques. For each class of dimeric compounds designed in accordance with the invention herein, a novel synthetic strategy was developed to allow variation in the length of the linking group through which the active molecules are joined. These synthetic strategies are set forth herein as Schemes 3 through 6 and in Examples 1 through 4 below. Use of the preferred method of variable linkage greatly increases the number of different tethered dimeric compounds that can be produced from a single pair of the same or different active molecules. The active molecules specifically disclosed herein may be used, as well as any pharmaceutically acceptable salts thereof.


As noted, pharmaceutically acceptable salts of the compounds set out herein below are also contemplated for use in this invention. Such salts are prepared by treating the free acid with an appropriate amount of a pharmaceutically acceptable base. Representative pharmaceutically acceptable bases are ammonium hydroxide, sodium hydroxide, potassium hydroxide, lithium hydroxide, calcium hydroxide, magnesium hydroxide, ferrous hydroxide, zinc hydroxide, copper hydroxide, aluminum hydroxide, ferric hydroxide, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, lysine, arginine, histidine,

and the like. The reaction is conducted in water, alone or in combination with an inert, water-miscible organic solvent, at a temperature of from about 0°C to about 100°C, preferably at room temperature. The molar ratio of compounds of structural formula (I) to base used are chosen to provide the ratio desired for any particular salts. For preparing, for example, the ammonium salts of the free acid starting material—a particular preferred embodiment—the starting material can be treated with approximately one equivalent of pharmaceutically acceptable base to yield a neutral salt. When calcium salts are prepared, approximately one-half a molar equivalent of base is used to yield a neutral salt, while for aluminum salts, approximately one-third a molar equivalent of base will be used.

Compounds prepared in accordance with the design and synthesis methods of this invention are especially attractive because they may preferably be further optimized by incorporation of substituents on either the active molecule and/or the linking group. These latter modifications can also preferably be accomplished using the combinatorial methods disclosed herein.

In a further embodiment of the present invention, selected novel compounds whose structures are designed by the above methods are synthesized individually using a novel strategy that allows variation in the length of the linking group. An example of a route preferably utilized to synthesize one class of dimers according to the present invention, using a single pair of active molecules, is summarized below in Scheme 3.

SCHEME 3.



In a preferred embodiment, the invention provides a method of making a bacterial NAD synthetase inhibitor compound comprising the steps of:

- alkylating 5-nitroindole with 6-bromohexyl acetate to form a 6-[N-(5-nitroindolyl)] hexyl acetate;
- hydrolyzing the 6-[N-(5-nitroindolyl)] hexyl acetate to form 6-[N-(5-nitroindolyl)]hexan-1-ol;
- esterifying the 6-[N-(5-nitroindolyl)]hexan-1-ol with nicotinic acid to form 6-[N-(5-nitroindolyl)]hexyl nicotinate; and
- N-methylating the 6-[N-(5-nitroindolyl)]hexyl nicotinate.


The following compounds were prepared according to Scheme 3 above, wherein n represents the number of linker groups tethering the two active molecules together.

Table 2: SAMPLE COMPOUND PREPARED ACCORDING TO SCHEME 3

Compound	N
862	3
863	4
864	5
865	6

Examples of additional preferred synthetic procedures utilized for preparing the library of the present invention are provided in Schemes 4-6. In Schemes 4-6, it is preferable to utilize combinatorial methods of synthesis using, for example, parallel solution phase synthesis techniques. One of skill in the art will readily recognize the manner in which the synthetic pathways disclosed below may be varied without departing from the novel and unobvious aspects of the invention.

Scheme 4




In a preferred embodiment, the invention provides a method of synthesizing a NAD synthetase inhibitor compound from the route set out in Scheme 4 above, comprising the steps of:

- alkylating 5-nitroindole with bromoalkyl acetate wherein the indole alkyl acetate is converted to indole alkyl alcohol;
- reacting the indole alkyl alcohol with the appropriate reagent to form an indole alkyl ester; and
- N*-methylating the indole alkyl ester.

In yet another embodiment, the invention provides a method of making a NAD synthetase inhibitor compound from the route set out in Scheme 4 above comprising the steps of:

- alkylating 5-nitroindole with bromoalkyl acetate wherein the indole alkyl acetate is converted to indole alkyl alcohol;
- reacting the indole alkyl alcohol with the appropriate reagent to form an indole alkyl ester; and
- reacting the indole alkyl alcohol with mesyl chloride followed by reaction with an amine to generate an ammonium product.


Scheme 5



In yet a further, still preferred, embodiment, the invention provides a method of making a NAD synthetase inhibitor from the route set out in Scheme 5 above, comprising the steps of:

- reacting indole carboxylic acid with the appropriate reagent to provide an indole carboxylate methyl ester or an indole benzyl carboxylate ester;
- N*-alkylating the indole carboxylate methyl ester or the indole carboxylate benzyl ester with bromoalkyl acetate;
- reacting the material from step b above with the appropriate reagent to form an indolealkyl alcohol;
- coupling the indolealkyl alcohol with an aromatic amine; and
- reacting the indolealkyl alcohol with the appropriate reagent to convert the methyl or benzyl indolecarboxylate to the respective indole carboxylic acids.

Scheme 6



In a further preferred embodiment, the invention provides a method of making a NAD synthetase inhibitor from the route set out in Scheme 6 above, comprising the steps of:


- a. brominating an aniline with N-bromosuccinimide to form a 2-bromo-R¹-substituted-aniline or a 2-bromo-R²-substituted-aniline;
- b. reacting the 2-bromo-R¹-substituted-aniline or the 2-bromo-R²-substituted-aniline using a Heck coupling reaction to form an alkyne-substituted aniline;
- c. reacting the alkyne-substituted aniline using a cyclization reaction to form an indole alcohol;
- d. quaternizing the indole alcohol with an amine;
- e. reacting the indole alcohol with methansulfonyl chloride to provide an indole mesylate; and
- f. reacting the indole mesylate with a carboxylic acid to form an indole ester.

In yet another preferred embodiment, the invention provides a method of making a NAD synthetase inhibitor compound from the route set out in Scheme 6 above, comprising the steps of:

- a. brominating an aniline with N-bromosuccinimide to form a 2-bromo-R¹-substituted-aniline or a 2-bromo-R²-substituted-aniline;
- b. reacting the 2-bromo-R¹-substituted-aniline or a 2-bromo-R²-substituted-aniline using a Heck coupling reaction to form an alkyne-substituted aniline;
- c. reacting the alkyne-substituted aniline using a cyclization reaction to form an indole alcohol;
- d. quaternizing the indole alcohol with an amine;
- e. reacting the indole alcohol with trifluoromethylsulfonic anhydride to provide a triflate; and
- f. reacting the indole triflate with an amine to form an indole alkylammonium product.

In a preferred embodiment, the invention provides a compound having the general structure of Structure 2:

STRUCTURE 2:




wherein:

n is an integer of from 1 to 12, $R_1 - R_7$ each, independently, is an H, an unsubstituted or a substituted cyclic or aliphatic group, a branched or an unbranched group, and wherein the linker is a cyclic or aliphatic, branched or an unbranched alkyl, alkenyl, or an alkynyl group and wherein the linker may also contain heteroatoms. By heteroatoms, it is meant that one or more atoms is an element other than carbon.

$R_1 - R_7$ may also be one of the following groups: an H, alkyl, alkenyl, alkynyl, or an aryl. $R_1 - R_7$ may further be a hydroxyl, ketone, nitro, amino, amidino, guanidino, carboxylate, amide, sulfonate, or halogen or the common derivatives of these groups. n may also be an integer of from 3 to 10, more preferably 5 to 9 and, still more preferably 6 to 9. The tethered active molecule, *e.g.*, in this example denoted "aryl," moieties may be the same or different.

In a further embodiment, the invention provides a compound of Structure 4:

STRUCTURE 4:




wherein:

X is a C, N, O or S within a monocyclic or bicyclic moiety, A and B represent the respective sites of attachment for the linker, n is an integer of from 1 to 12, R₁-R₇ each, independently, is an H, an unsubstituted or a substituted cyclic group, or an aliphatic group, or a branched or an unbranched group, and the linker is a saturated or unsaturated cyclic group or an aliphatic branched or unbranched alkyl, alkenyl or alkynyl group, and wherein the linker may also contain heteroatoms.

R₁-R₇ may also be one of the following groups: an H, alkyl, alkenyl, alkynyl, or an aryl group. R₁-R₇ may also be a hydroxyl, ketone, nitro, amino, amidino, guanidino, carboxylate, amide, sulfonate, or halogen or the common derivatives of these groups. One of skill in the art would know what moieties are considered to constitute derivatives of these groups. N may also be an integer of from 3 to 10, more preferably 5 to 9 and, still more preferably 6 to 9.

In a further embodiment, the invention provides a compound of Structure 6:

STRUCTURE 6:



wherein:

X is C, N, O or S, Y is C, N, O, S, carboxy, ester, amide, or ketone, A and B represent the respective sites of attachment for a linker, n is an integer of from 1 to 12, and R_1 - R_7 each, independently, is an H, unsubstituted or substituted cyclic group or an aliphatic group, a branched or an unbranched group, and the linker is a saturated or unsaturated cyclic or aliphatic group, branched or unbranched alkyl, alkenyl, or alkynyl group and wherein the linker may also contain heteroatoms.


R_1 - R_7 may also be one of the following groups: an H, alkyl, alkenyl, or alkynyl, or an aryl group. R_1 - R_7 may also be an H, hydroxyl, ketone, nitro, amino, amidino, guanidino, carboxylate, amide, sulfonate, or halogen and the common derivatives of these groups. One of skill in the art would know what moieties are considered to constitute derivatives of these groups. N may also be an integer of from 3 to 10, more preferably 5 to 9 and, still more preferably 6 to 9.

In a further embodiment, the invention provides a compound of Structure 8:

WO 99/36422

41

PCT/US99/00810


STRUCTURE 8:

wherein:

n is an integer of from 1 to 12, R_1 is an H, methoxy, benzyloxy, or nitro and R_2 is 3-pyridyl, N-methyl-3-pyridyl, 3-quinolinyl, N-methyl-3-quinolinyl, 3-(dimethylamino)phenyl, 3-(trimethylammonio)phenyl, 4-(dimethylamino)phenyl, 4-(trimethylammonio)phenyl, 4-(dimethylamino)phenylmethyl, or 4-(trimethylammonio)phenylmethyl.

N may also be an integer of from 3 to 10, more preferably 5 to 9 and, still more preferably 6 to 9.

In a further embodiment, the invention provides a compound of Structure 10:

STRUCTURE 10:


wherein:

n is an integer of from 1 to 12, R_1 is an H, CO_2H , $-\text{OCH}_3$, or $-\text{OCH}_2\text{Ph}$, R_2 is H, CO_2H , or $\text{CH}=\text{CHCO}_2\text{H}$, R_3 is H or CO_2H , and Y is N-linked pyridine-3-carboxylic acid, N-linked pyridine, N-linked quinoline, or N-linked isoquinoline. N may also be an integer of from

3 to 10, more preferably 5 to 9 and, still more preferably 6 to 9.

In a further embodiment, the invention provides a compound of Structure 12:

STRUCTURE 12:




wherein:

n is an integer of from 1 to 12, R₁ is H, F, or NO₂, R₂ is H, CH₃, CF₃, NO₂, phenyl, n-butyl, isopropyl, F, phenyloxy, triphenylmethyl, methoxycarbonyl, methoxy, carboxy, acetyl, or benzoyl, R₃ is H or CF₃, and Y is N-linked pyridine-3-carboxylic acid, N-linked pyridine, N-linked quinoline, or N-linked isoquinoline. N may also be an integer of from 3 to 10, more preferably 5 to 9 and, still more preferably 6 to 9.

In a further embodiment, the invention provides a compound of Structure 14:

STRUCTURE 14:




wherein:

n is an integer of from 1 to 12, R₁ is H, phenyloxy, isopropyl, acetyl, or benzoyl, R₂ is H or CF₃, and Y is 3-(dimethylamino)phenyl, 3-(trimethylammonio)phenyl, 4-(dimethylamino)phenyl, 4-(trimethylammonio)phenyl, 2-(phenyl)phenyl, diphenylmethyl,

3-pyridyl, 4-pyridyl, or pyridine-3-methyl. N may also be an integer of from 3 to 10, more preferably 5 to 9 and, still more preferably 6 to 9.


In a further embodiment, the invention provides a compound of Structure 16:



STRUCTURE 16

wherein R is H or CO_2CH_3 , and n is an integer of from 1 to 4, more preferably 2 to 3, and even more preferably, n is 3.

In a further embodiment, the invention provides a compound of Structure 18:



STRUCTURE 18

wherein R is H or CO_2CH_3 , and n is an integer of from 1 to 4, more preferably 2 to 3, and

even more preferably, n is 3.

In further preferred embodiments of the invention herein, compounds of the structures denoted in Tables 102-128 as Compounds 1-274 were synthesized utilizing the methods disclosed herein. For Compounds 1-274, structures denoted in Figure 6 as Fragments I-X each represent an active molecule, as defined previously herein, which can be included in the compounds of the present invention as further described in the respective Tables. In Fragments I-X of Figure 6, the point of attachment for the linker compound is at the nitrogen.

In the chemical structures that follow, and as intended for the compounds of this invention, the symbol T⁻ designates generally the presence of an anion. As contemplated by the present invention, the type of anion in the compounds of this invention is not critical. The anions present in the compounds of this may be comprised of any such moieties known generally to one of skill in the art or that follow from the synthesis methods disclosed herein.






FIGURE 6: FRAGMENTS UTILIZED IN COMPOUNDS 1-274

In preferred embodiments of the invention herein, the compounds of the present invention correspond to Structure 100:



Structure 100

wherein R' is:



and n is an integer of from 1 to 12. N may also be from 3 to 10, more preferably 5 to 9 and, still more preferably 6 to 9.

In further preferred embodiments of the invention herein, the compounds of the present invention correspond to the structures set out in Structure 100 and as further defined in Table 100. For those compounds that correspond to Structure 100, n may also be an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9.

STRUCTURE 100:





TABLE 100: SUBSTITUENT GROUPS FOR COMPOUNDS 1-24

R'	n=	3	4	5	6	7	8	9
I		1	2	3	4	5	6	7
II		8	9	10	11	12	13	14
III		15	16	17	18	19	20	21
IV						22		
V						23		
VI						24		

In the above Table, R' corresponds to a Fragment as previously defined in Figure 6 and n indicates the number of linker groups separating the two tethered active molecule groups in the compound.

As set out below in relation to Compounds 25 - 274, Fragments A - G are set out in Figure 8. The group denoted R in A-G of Figure 8 can be a benzyl group, a methyl group or a hydrogen. The point of attachment of the linker group to Fragments A-G is at the nitrogen group.

In one embodiment, the compounds of the present invention correspond to compounds of Structure 101. For those compounds that correspond to Structure 101, n is an integer of from 1 to 12, more preferably from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9. The point of attachment of the linker group for both R1 and R' is at the respective nitrogen groups of each illustrated fragment.






Structure 101

WO 99/36422


48

PCT/US99/00810

wherein R' is:



wherein R1 is:



wherein the R group in Fragments A-G is a benzyl group, a methyl group or a hydrogen.

In one embodiment of the invention herein, the compounds of the present invention may include the Fragments illustrated below in Figure 8.




FIGURE 8: FRAGMENTS A-G IN COMPOUNDS 25-274

In further preferred embodiments of the invention herein, the compounds of the present invention correspond to the structures set out in Structure 102. For those compounds that correspond to Structure 102, n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9. In further embodiments, the compounds herein correspond to Structure 102, as further set out in Table 102.

STRUCTURE 102:




TABLE 102: SUBSTITUENT GROUPS FOR COMPOUNDS 25-48

R'	n=	4	6	8
I		25	26	27
I*		28	29	30
II		31	32	33
III*		34	35	36
VII		37	38	39
VII*		40	41	42
VIII		43	44	45
VIII*		46	47	48

In the above Table, R' corresponds to a Fragment as previously defined in Figure 6, A corresponds to a Fragment as previously defined in Figure 8, and n indicates the number of linker groups separating Groups R' and A in the respective compounds. Groups I, II, VII, VIII each have a benzyl group and Groups I*, III*, VII*, VIII* each have a hydrogen, respectively, in the position designated R in Fragment A of Figure 8.

In further preferred embodiments of the invention herein, the compounds of the present invention correspond to the structures set out in Structure 104. For those compounds that correspond to Structure 104, n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9. In further embodiments, the compounds herein correspond to Structure 104, as further set out in Table 104.


STRUCTURE 104:

TABLE 104: SUBSTITUENT GROUPS FOR COMPOUNDS 49-66

R' n=	4	6	8
I	49	50	51
I*	52	53	54
VII	55	56	57
VII*	58	59	60
VIII	61	62	63
VIII*	64	65	66

In the above Table, R' corresponds to a Fragment as previously defined in Figure 6, B corresponds to a Fragment as previously defined in Figure 8, and n indicates the number of linker groups separating Groups R' and B in the respective compounds. Groups I, VII, VIII each have a benzyl group and Groups I*, VII*, VIII* each have a hydrogen, respectively, in the position designated R in Fragment B of Figure 8.

In further preferred embodiments of the invention herein, the compounds of the present invention correspond to the structures set out in Structure 106. For those compounds that correspond to Structure 106, n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9. In further embodiments, the compounds herein correspond to Structure 106, as further set out in Table 106.


STRUCTURE 106:

TABLE 106: SUBSTITUENT GROUPS FOR COMPOUNDS 67-90

R'	n=	4	6	8
I		67	68	69
I*		70	71	72
II		73	74	75
III*		76	77	78
VII		79	80	81
VII*		82	83	84
VIII		85	86	87
VIII*		88	89	90

In the above Table, R' corresponds to a Fragment as previously defined in Figure 6, C corresponds to a Fragment as previously defined in Figure 8, and n indicates the number of linker groups separating Groups R' and C in the respective compounds. Groups I, II, VII, VIII each have a benzyl group and Groups I*, III*, VII*, VIII* each have a hydrogen, respectively, in the position designated R in Fragment C of Figure 8.

In further preferred embodiments of the invention herein, the compounds of the present invention correspond to the structures set out in Structure 108. For those compounds that correspond to Structure 108, n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9. In further embodiments, the compounds herein correspond to Structure 108, as further set out in Table 108.

STRUCTURE 108:



TABLE 108: SUBSTITUENT GROUPS FOR COMPOUNDS 91-108

R' n =	4	6	8
I	91	92	93
I*	94	95	96
VII	97	98	99
VII*	100	101	102
VIII	103	104	105
VIII*	106	107	108

In the above Table, R' corresponds to a Fragment as previously defined in Figure 6, D corresponds to a fragment as previously defined in Figure 8, and n indicates the number of linker groups separating Groups R' and D in the compound. Groups I, VII, VIII each have a benzyl group and Groups I*, VII*, VIII* each have a hydrogen, respectively, in the position designated R in Fragment D of Figure 8.

In further preferred embodiments of the invention herein, the compounds of the present invention correspond to the structures set out in Structure 110. For those compounds that correspond to Structure 110, n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9. In further embodiments, the compounds herein correspond to Structure 110, as further set out in Table 110.

STRUCTURE 112:




TABLE 112: SUBSTITUENT GROUPS FOR COMPOUNDS 127-144

R' n=	4	6	8
I	127	128	129
I*	130	131	132
VII	133	134	135
VII*	136	137	138
VIII	139	140	141
VIII*	142	143	144

In the above Table, R' corresponds to a Fragment as previously defined in Figure 6, F corresponds to a Fragment as previously defined in Figure 8, and n indicates the number of linker groups separating Groups R' and F in the respective compounds. Groups I, VII, VIII each have a benzyl group and Groups I*, VII*, VIII* each have a hydrogen, respectively, in the position designated R in Fragment F of Figure 8.

In further preferred embodiments of the invention herein, the compounds of the present invention correspond to the structures set out in Structure 114. For those compounds that correspond to Structure 114, n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9. In further embodiments, the compounds herein correspond to Structure 114, as further set out in Table 114.

STRUCTURE 114:




TABLE 114: SUBSTITUENT GROUPS FOR COMPOUNDS 145-162

R' n=	4	6	8
I	145	146	147
I*	148	149	150
VII	151	152	153
VII*	154	155	156
VIII	157	158	159
VIII*	160	161	162

In the above Table, R' corresponds to a Fragment as previously defined in Figure 6, G corresponds to a Fragment as previously defined in Figure 8, and n indicates the number of linker groups separating Groups R' and G in the respective compounds. Groups I, VII, VIII each have a benzyl group and Groups I*, VII*, VIII* each have a hydrogen, respectively, in the position designated R in Fragment G of Figure 8.

In further preferred embodiments of the invention herein, the compounds of the present invention correspond to the structures set out in Structure 116. For those compounds that correspond to Structure 116, n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9. In further embodiments, the compounds herein correspond to Structure 116, as further set out in Table 116.

STRUCTURE 116:




TABLE 116: SUBSTITUENT GROUPS FOR COMPOUNDS 163-178

R'	n=	3	5	7	9
I		163	164	165	166
I*		167	168	169	170
II		171	172	173	174
III*		175	176	177	178

In the above Table, R' corresponds to a Fragment as previously defined in Figure 6, A corresponds to a Fragment as previously defined in Figure 8, and n indicates the number of linker groups separating Groups R' and A in the respective compounds. Groups I, II each have a methyl group and Groups I*, III* each have a hydrogen, respectively, in the position designated R in Fragment A of Figure 8.

In further preferred embodiments of the invention herein, the compounds of the present invention correspond to the structures set out in Structure 118. For those compounds that correspond to Structure 118, n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9. In further embodiments, the compounds herein correspond to Structure 118, as further set out in Table 118.

STRUCTURE 118:




TABLE 118: SUBSTITUENT GROUPS FOR COMPOUNDS 179-194

R'	n=	3	5	7	9
I		179	180	181	182
I*		183	184	185	186
II		187	188	189	190
III*		191	192	193	194

In the above Table, R' corresponds to a Fragment as previously defined in Figure 6, B corresponds to a Fragment as previously defined in Figure 8, and n indicates the number of linker groups separating Groups R' and B in the respective compounds. Groups I, II each have a methyl group and Groups I*, III* each have a hydrogen, respectively, in the position designated R in Fragment B of Figure 8.

In further preferred embodiments of the invention herein, the compounds of the present invention correspond to the structures set out in Structure 120. For those compounds that correspond to Structure 120, n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9. In further embodiments, the compounds herein correspond to Structure 120, as further set out in Table 120.

WO 99/36422

60

PCT/US99/00810

STRUCTURE 120:




TABLE 120: SUBSTITUENT GROUPS FOR COMPOUNDS 195-210

R'	n=	3	5	7	9
I		195	196	197	198
I*		199	200	201	202
II		203	204	205	206
III*		207	208	209	210

In the above Table, R' corresponds to a Fragment as previously defined in Figure 6, C corresponds to a Fragment as previously defined in Figure 8, and n indicates the number of linker groups separating Groups R' and C in the respective compounds. Groups I, II each have a methyl group and Groups I*, II* each have a hydrogen, respectively, in the position designated R in Fragment C of Figure 8.

In further preferred embodiments of the invention herein, the compounds of the present invention correspond to the structures set out in Structure 122. For those compounds that correspond to Structure 122, n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9. In further embodiments, the compounds herein correspond to Structure 122, as further set out in Table 122.

WO 99/36422

61

PCT/US99/00810

STRUCTURE 122:




TABLE 122: SUBSTITUENT GROUPS FOR COMPOUNDS 211-226

R' n=	3	5	7	9
I	211	212	213	214
I*	215	216	217	218
II	219	220	221	222
III*	223	224	225	226

In the above Table, R' corresponds to a Fragment as previously defined in Figure 6, D corresponds to a Fragment as previously defined in Figure 8, and n indicates the number of linker groups separating Groups R' and D in the respective compounds. Groups I, II each have a methyl group and Groups I, III each have a hydrogen, respectively, in the position designated R in Fragment D of Figure 8.

In further preferred embodiments of the invention herein, the compounds of the present invention correspond to the structures set out in Structure 124. For those compounds that correspond to Structure 124, n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9. In further embodiments, the compounds herein correspond to Structure 124, as further set out in Table 124.

STRUCTURE 124:





TABLE 124: SUBSTITUENT GROUPS FOR COMPOUNDS 227-242

R'	n=	3	5	7	9
I		227	228	229	230
I*		231	232	233	234
II		235	236	237	238
III*		239	240	241	242

In the above Table, R' corresponds to a Fragment as previously defined in Figure 6, E corresponds to a Fragment as previously defined in Figure 8, and n indicates the number of linker groups separating Groups R' and E in the respective compounds. Groups I, II each have a methyl group and Groups I*, III* each have a hydrogen, respectively, in the position designated R in Fragment E of Figure 8.

In further preferred embodiments of the invention herein, the compounds of the present invention correspond to the structures set out in Structure 126. For those compounds that correspond to Structure 126, n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9. In further embodiments, the compounds herein correspond to Structure 126, as further set out in Table 126.

STRUCTURE 126:



WO 99/36422

63

PCT/US99/00810

TABLE 126: SUBSTITUENT GROUPS FOR COMPOUNDS 243-258

R' n=	3	5	7	9
I	243	244	245	246
I*	247	248	249	250
II	251	252	253	254
III*	255	256	257	258

In the above Table, R' corresponds to a Fragment as previously defined in Figure 6, F corresponds to a Fragment as previously defined in Figure 8, and n indicates the number of linker groups separating Groups R' and F in the respective compounds. Groups I, II each have a methyl group and Groups I*, III* each have a hydrogen, respectively, in the position designated R in Fragment F of Figure 8.

In further preferred embodiments of the invention herein, the compounds of the present invention correspond to the structures set out in Structure 128. For those compounds that correspond to Structure 128, n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9. In further embodiments, the compounds herein correspond to Structure 128, as further set out in Table 128.


STRUCTURE 128:

TABLE 128: SUBSTITUENT GROUPS FOR COMPOUNDS 259-274

R'	n=	3	5	7	9
I		259	260	261	262
I*		263	264	265	266
II		267	268	269	270
III*		271	272	273	274

In the above Table, R' corresponds to a Fragment as previously defined in Figure 6, G corresponds to a Fragment as previously defined in Figure 6, and n indicates the number of linker groups separating Groups R' and G in the respective compounds. Groups I, II each have a methyl group and Groups I*, III* each have a hydrogen, respectively, in the position designated R in Fragment G of Figure 8.

As used herein, the following terms are defined as follows: Ph: phenyl; I-propyl= isopropyl; OPh =O-Phenyl; and diNO₂=dinitric.

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 130 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9. Further preferred embodiments of the compounds corresponding to Structure 130 are set out in Table 130.

STRUCTURE 130:





TABLE 130: COMPOUNDS CORRESPONDING TO STRUCTURE 130

n =	3	4	5	6	7	8	9
	275	276	277	278	279	280	281

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 132 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 5-H, 6-CF₃, 5-CH₃, 5,7-diF, 5,7-diNO₂, 5-Butyl, 5-iPropyl, 5-Phenyl, 5-NO₂, 5-Trityl, 5-F, 5-OPh, 5-COPh, 5-CF₃, 5-COCH₃, 5-OCH₃, 5-COOCH₃, or 5-COOH.

Further preferred embodiments of the compounds corresponding to Structure 132 are set out in Table 132.

STRUCTURE 132:**TABLE 132: COMPOUNDS 282-389 CORRESPONDING TO STRUCTURE 132**

R	n=	3	4	5	6	7	8
5-H		282	283	284	285	286	287
6-CF ₃		288	289	290	291	292	293
5-CH ₃		294	295	296	297	298	299
5,7-diF		300	301	302	303	304	305
5,7-diNO ₂		306	307	308	309	310	311

WO 99/36422

66

PCT/US99/00810

5-Butyl	312	313	314	315	316	317
5-iPropyl	318	319	320	321	322	323
5-Phenyl	324	325	326	327	328	329
5-NO ₂	330	331	332	333	334	335
5-Trityl	336	337	338	339	340	341
5-F	342	343	344	345	346	347
5-OPh	348	349	350	351	352	353
5-COPh	354	355	356	357	358	359
5-CF ₃	360	361	362	363	364	365
5-COCH ₃	366	367	368	369	370	371
5-OCH ₃	372	373	374	375	376	377
5-COOCH ₃	378	379	380	381	382	383
5-COOH	384	385	386	387	388	389

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 134 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 5-H, 6-CF₃, 5-CH₃, 5,7-diF, 5,7-diNO₂, 5-Butyl, 5-iPropyl, 5-Phenyl, 5-NO₂, 5-Trityl, 5-F, 5-OPh, 5-COPh, 5-CF₃, 5-COCH₃, 5-OCH₃, 5-COOCH₃, or 5-COOH. Further preferred embodiments of the compounds corresponding to Structure 134 are set out in Table 134.

STRUCTURE 134:




TABLE 134: COMPOUNDS 390-497 CORRESPONDING TO STRUCTURE 134

R	n=	3	4	5	6	7	8
5-H		390	391	392	393	394	395
6-CF ₃		396	397	398	399	400	401
5-CH ₃		402	403	404	405	406	407
5,7-diF		408	409	410	411	412	413
5,7-diNO ₂		414	415	416	417	418	419
5-Butyl		420	421	422	423	424	425
5-iPropyl		426	427	428	429	430	431
5-Phenyl		432	433	434	435	436	437
5-NO ₂		438	439	440	441	442	443
5-Trityl		444	445	446	447	448	449
5-F		450	451	452	453	454	455
5-OPh		456	457	458	459	460	461
5-COPh		462	463	464	465	466	467
5-CF ₃		468	469	470	471	472	473
5-COCH ₃		474	475	476	477	478	479
5-OCH ₃		480	481	482	483	484	485
5-COOCH ₃		486	487	488	489	490	491
5-COOH		492	493	494	495	496	497

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 136 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 5-H, 6-CF₃, 5-CH₃, 5,7-diF, 5,7-diNO₂, 5-Butyl, 5-iPropyl, 5-Phenyl, 5-NO₂, 5-Trityl, 5-F, 5-OPh, 5-COPh, 5-CF₃, 5-COCH₃, 5-OCH₃, 5-COOCH₃, or 5-COOH. Further preferred embodiments of the compounds corresponding to Structure 136 are set out in Table 136.

WO 99/36422

68

PCT/US99/00810

STRUCTURE 136:




TABLE 136: COMPOUNDS 498-605 CORRESPONDING TO STRUCTURE 136

R	n=	3	4	5	6	7	8
5-H		498	499	500	501	502	503
6-CF ₃		504	505	506	507	508	509
5-CH ₃		510	511	512	513	514	515
5,7-diF		516	517	518	519	520	521
5,7-diNO ₂		522	523	524	525	526	527
5-Butyl		528	529	530	531	532	533
5-iPropyl		534	535	536	537	538	539
5-Phenyl		540	541	542	543	544	545
5-NO ₂		546	547	548	549	550	551
5-Trityl		552	553	554	555	556	557
5-F		558	559	560	561	562	563
5-OPh		564	565	566	567	568	569
5-COPh		570	571	572	573	574	575
5-CF ₃		576	577	578	579	580	581
5-COCH ₃		582	583	584	585	586	587
5-OCH ₃		588	589	590	591	592	593
5-COOCH ₃		594	595	596	597	598	599
5-COOH		600	601	602	603	604	605


In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 138 wherein n is an integer of from 1 to 12,

WO 99/36422

69

PCT/US99/00810

more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 5-CF₃, 5-OPh, 5-iPropyl, 5-COCH₃, or 5-COPh and Y is 3-N,N-dimethylaminophenyl (3-N,N-diCH₃), 4-N,N-dimethylaminophenyl (4-N,N-diCH₃), or 2-Ph. Further preferred embodiments of the compounds corresponding to Structure 138 are set out in Table 138.

STRUCTURE 138:**TABLE 138: COMPOUNDS 606-650 CORRESPONDING TO STRUCTURE 138**

R	n=	4	7	8	Y
5-CF ₃		606	607	608	3-N,N-DiCH ₃
5-CF ₃		609	610	611	4-N,N-DiCH ₃
5-CF ₃		612	613	614	2-Ph
5-OPh		615	616	617	3-N,N-DiCH ₃
5-OPh		618	619	620	4-N,N-DiCH ₃
5-OPh		621	622	623	2-Ph
5-iPropyl		624	625	626	3-N,N-DiCH ₃
5-iPropyl		627	628	629	4-N,N-DiCH ₃
5-iPropyl		630	631	632	2-Ph
5-COCH ₃		633	634	635	3-N,N-DiCH ₃
5-COCH ₃		636	637	638	4-N,N-DiCH ₃
5-COCH ₃		639	640	641	2-Ph
5-COPh		642	643	644	3-N,N-DiCH ₃
5-COPh		645	646	647	4-N,N-DiCH ₃


WO 99/36422

70

PCT/US99/00810

5-COPh	648	649	650	2-Ph
--------	-----	-----	-----	------

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 140 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 5-CF₃, 5-OPh, 5-iPropyl, 5-COCH₃, or 5-COPh, and Z is CH(Ph)₂ or 3-Pyridyl. Further preferred embodiments of the compounds corresponding to Structure 140 are set out in Table 140.

STRUCTURE 140:**TABLE 140: COMPOUNDS 651-680 CORRESPONDING TO STRUCTURE 140**

R	n=	4	7	8	Z
5-CF ₃		651	652	653	CH(Ph) ₂
5-CF ₃		654	655	656	3-Pyridyl
5-OPh		657	658	659	CH(Ph) ₂
5-OPh		660	661	662	3-Pyridyl
5-iPropyl		663	664	665	CH(Ph) ₂
5-iPropyl		666	667	668	3-Pyridyl
5-COCH ₃		669	670	671	CH(Ph) ₂
5-COCH ₃		672	673	674	3-Pyridyl
5-COPh		675	676	677	CH(Ph) ₂
5-COPh		678	679	680	3-Pyridyl

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 142 wherein n is an integer of from 1 to 12,

more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 6-CF₃, 5-OPh, 5-iPropyl, 5-COCH₃, or 5-COPh. Further preferred embodiments of the compounds corresponding to Structure 142 are set out in Table 142.

STRUCTURE 142:




TABLE 142: COMPOUNDS 681-695 CORRESPONDING TO STRUCTURE 142

R	n=	4	7	8
6-CF ₃		681	682	683
5-Oph		684	685	686
5-iPropyl		687	688	689
5-COCH ₃		690	691	692
5-COPh		693	694	695

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 144 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 6-CF₃, 5-OPh, 5-iPropyl, 5-COCH₃, or 5-COPh. Further preferred embodiments of the compounds corresponding to Structure 144 are set out in Table 144.

STRUCTURE 144:




TABLE 144: COMPOUNDS 696-710 CORRESPONDING TO STRUCTURE 144

R	n=	4	7	8
6-CF ₃		696	697	698
5-OPh		699	700	701
5-iPropyl		702	703	704
5-COCH ₃		705	706	707
5-COPh		708	709	710

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 146 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9. Further preferred embodiments of the compounds corresponding to Structure 146 are set out in Table 146.

STRUCTURE 146:




TABLE 146: COMPOUNDS 711-714 CORRESPONDING TO STRUCTURE 146

n=	3	4	5	8
	711	712	713	714

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 148, as further defined in Table 148.

STRUCTURE 148:




TABLE 148: COMPOUND 715 CORRESPONDING TO STRUCTURE 148

715

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 150 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9.

Further preferred embodiments of the compounds corresponding to Structure 150 are set out in Table 150.

STRUCTURE 150:




TABLE 150: COMPOUNDS 716-718 CORRESPONDING TO STRUCTURE 150

n=	2	3	4
	716	717	718

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 152 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9.

Further preferred embodiments of the compounds corresponding to Structure 152 are set out in Table 152.

STRUCTURE 152:




TABLE 152: COMPOUNDS 719-725 CORRESPONDING TO STRUCTURE 152

n=	3	4	5	6	7	8	9
	719	720	721	722	723	724	725

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 154 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein Z is $\text{CH}(\text{DiPh})$, 4-(N,N-dimethylamino)phenyl, CH_2CH_2 -(3-pyridyl), or (2-phenyl)-phenyl. Further preferred embodiments of the compounds corresponding to Structure 154 are set out in Table 154.

STRUCTURE 154:




TABLE 154: COMPOUNDS 726-729 CORRESPONDING TO STRUCTURE 154

Z=	CH(DiPh)	(4-N,N-DiCH ₃)phenyl	CH ₂ CH ₂ -(3-pyridyl)	(2-phenyl)-phenyl
	726	727	728	729

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 156 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is -OCH₃ or -OCH₂Ph. Further preferred embodiments of the compounds corresponding to Structure 156 are set out in Table 156.

STRUCTURE 156:




TABLE 156: COMPOUNDS 730-739 CORRESPONDING TO STRUCTURE 156

R	n=	4	5	6	7	8
-OCH ₃		730	731	732	733	734
-OCH ₂ Ph		735	736	737	738	739

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 158 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is $-OCH_3$ or $-OCH_2Ph$. Further preferred embodiments of the compounds corresponding to Structure 158 are set out in Table 158.

STRUCTURE 158:




TABLE 158: COMPOUNDS 740-749 CORRESPONDING TO STRUCTURE 158

R	n=	4	5	6	7	8
$-OCH_3$		740	741	742	743	744
$-OCH_2Ph$		745	746	747	748	749

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 160 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is $-OCH_3$ or $-OCH_2Ph$. Further preferred embodiments of the compounds corresponding to Structure 160 are set out in Table 160.

WO 99/36422

77

PCT/US99/00810

STRUCTURE 160:




TABLE 160: COMPOUNDS 750-759 CORRESPONDING TO STRUCTURE 160

R	n=	4	5	6	7	8
-OCH ₃		750	751	752	753	754
-OCH ₂ Ph		755	756	757	758	759

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 162 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is -OCH₃ or -OCH₂Ph. Further preferred embodiments of the compounds corresponding to Structure 162 are set out in Table 162.

STRUCTURE 162:




TABLE 162: COMPOUNDS 760-769 CORRESPONDING TO STRUCTURE 162

R	n=	4	5	6	7	8
-OCH ₃		760	761	762	763	764
-OCH ₂ Ph		765	766	767	768	769

In further embodiments, the compounds of the present invention preferably

correspond to compounds of the Structure 164 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is $-\text{OCH}_3$ or $-\text{OCH}_2\text{Ph}$. Further preferred embodiments of the compounds corresponding to Structure 164 are set out in Table 164.

STRUCTURE 164:




TABLE 164: COMPOUNDS 770-779 CORRESPONDING TO STRUCTURE 164

R	n=	4	5	6	7	8
$-\text{OCH}_3$		770	771	772	773	774
$-\text{OCH}_2\text{Ph}$		775	776	777	778	779

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 166 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is $-\text{OCH}_3$ or $-\text{OCH}_2\text{Ph}$. Further preferred embodiments of the compounds corresponding to Structure 166 are set out in Table 166.

WO 99/36422

79

PCT/US99/00810

STRUCTURE 166:





TABLE 166: COMPOUNDS 780-789 CORRESPONDING TO STRUCTURE 166

R	n=	4	5	6	7	8
-OCH ₃		780	781	782	783	784
-OCH ₂ Ph		785	786	787	788	789

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 168 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is -OCH₃ or -OCH₂Ph. Further preferred embodiments of the compounds corresponding to Structure 168 are set out in Table 168.

STRUCTURE 168:



WO 99/36422


80

PCT/US99/00810

TABLE 168: COMPOUNDS 790-799 CORRESPONDING TO STRUCTURE 168

R	n=	4	5	6	7	8
-OCH ₃		790	791	792	793	794
-OCH ₂ Ph		795	796	797	798	799

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 170 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is -OCH₃ or -OCH₂Ph. Further preferred embodiments of the compounds corresponding to Structure 170 are set out in Table 170.

STRUCTURE 170:**TABLE 170: COMPOUNDS 800-809 CORRESPONDING TO STRUCTURE 170**

R	n=	4	5	6	7	8
-OCH ₃		800	801	802	803	804
-OCH ₂ Ph		805	806	807	808	809

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 172 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is -OCH₃ and -OCH₂ Ph. Further preferred embodiments of the compounds corresponding to Structure 172 are set out in Table 172.

STRUCTURE 172:




TABLE 172: COMPOUNDS 810-819 CORRESPONDING TO STRUCTURE 172

R	n=	4	5	6	7	8
-OCH ₃		810	811	812	813	814
-OCH ₂ Ph		815	816	817	818	819

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 174 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is -OCH₃ and -OCH₂ Ph. Further preferred embodiments of the compounds corresponding to Structure 174 are set out in Table 174.

STRUCTURE 174:




TABLE 174: COMPOUNDS 820-829 CORRESPONDING TO STRUCTURE 174

R	n=	4	5	6	7	8
-OCH ₃		820	821	822	823	824
-OCH ₂ Ph		825	826	827	828	829

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 176 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein Z is 3-quinoline, 3-(N,N-dimethylamino)phenyl, or 4-(N,N-dimethylamino)phenyl. Further preferred embodiments of the compounds corresponding to Structure 176 are set out in Table 176.

STRUCTURE 176:




TABLE 176: COMPOUNDS 830-847 CORRESPONDING TO STRUCTURE 176

Z	n=	4	5	6	7	8	9
3-quinoline		830	831	832	833	834	835
3-(N,N-diCH ₃) phenyl		836	837	838	839	840	841
4-(N,N-diCH ₃) phenyl		842	843	844	845	846	847

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 178 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from


WO 99/36422

83

PCT/US99/00810

6 to 9.


Further preferred embodiments of the compounds corresponding to Structure 178 are set out in Table 178.

STRUCTURE 178:**TABLE 178: COMPOUNDS 848-853 CORRESPONDING TO STRUCTURE 178**

N=	4	5	6	7	8	9
	848	849	850	851	852	853

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 180 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9.

Further preferred embodiments of the compounds corresponding to Structure 180 are set out in Table 180.

**STRUCTURE 180:****TABLE 180: COMPOUNDS 854-860 CORRESPONDING TO STRUCTURE 180**

WO 99/36422

84

PCT/US99/00810

n=	2	3	4	5	6	7	8
	854	855	856	857	858	859	860

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 182 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9.

Further preferred embodiments of the compounds corresponding to Structure 182 are set out in Table 182.

STRUCTURE 182:




TABLE 182: COMPOUNDS 861-867 CORRESPONDING TO STRUCTURE 182

n=	2	3	4	5	6	7	8
	861	862	863	864	865	866	867

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 184 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 6-CF₃, 5-OPh, 5-CH(CH₃)₂, 5-COCH₃ or 5-COPh. Further preferred embodiments of the compounds corresponding to Structure 184 are set out in Table 184.

STRUCTURE 184:




TABLE 184: COMPOUNDS 868-882 CORRESPONDING TO STRUCTURE 184

R	n=	4	7	8
6-CF ₃		868	869	870
5-Oph		871	872	873
5-CH(CH ₃) ₂		874	875	876
5-COCH ₃		877	878	879
5-COPh		880	881	882

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 186 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 6-CF₃, 5-OPh, 5-CH(CH₃)₂, 5-COCH₃, or 5-COPh. Further preferred embodiments of the compounds corresponding to Structure 186 are set out in Table 186.

STRUCTURE 186:




TABLE 186: COMPOUNDS 883-897 CORRESPONDING TO STRUCTURE 186

R	n=	4	7	8
6-CF ₃		883	884	885
5-Oph		886	887	888
5-CH(CH ₃) ₂		889	890	891
5-COCH ₃		892	893	894
5-COPh		895	896	897

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 188 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 6-CF₃, 5-Oph, 5-CH(CH₃)₂, 5-COCH₃ or 5-COPh. Further preferred embodiments of the compounds corresponding to Structure 188 are set out in Table 188.

STRUCTURE 188:




TABLE 188: COMPOUNDS 898-912 CORRESPONDING TO STRUCTURE 188

R	n=	4	7	8
6-CF ₃		898	899	900
5-Oph		901	902	903
5-CH(CH ₃) ₂		904	905	906
5-COCH ₃		907	908	909
5-COPh		910	911	912

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 190 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 6-CF₃, 5-Oph, 5-CH(CH₃)₂, 5-COCH₃ or 5-COPh. Further preferred embodiments of the compounds corresponding to Structure 190 are set out in Table 190.

STRUCTURE 190:




TABLE 190: COMPOUNDS 913-927 CORRESPONDING TO STRUCTURE 190

R	n=	4	7	8
6-CF ₃		913	914	915
5-Oph		916	917	918
5-CH(CH ₃) ₂		919	920	921
5-COCH ₃		922	923	924
5-COPh		925	926	927

WO 99/36422

88

PCT/US99/00810

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 192 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 6-CF₃, 5-OPh, 5-CH(CH₃)₂, 5-COCH₃ or 5-COPh. Further preferred embodiments of the compounds corresponding to Structure 192 are set out in Table 192.

STRUCTURE 192:




TABLE 192: COMPOUNDS 928-942 CORRESPONDING TO STRUCTURE 192

R	n=	4	7	8
6-CF ₃		928	929	930
5-OPh		931	932	933
5-CH(CH ₃) ₂		934	935	936
5-COCH ₃		937	938	939
5-COPh		940	941	942

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 194 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and R^1 is an H or -OCH₂Ph and R^2 is H or COOCH₃. Further preferred embodiments of the compounds corresponding to Structure 194 are set out in Table 194.

WO 99/36422

89

PCT/US99/00810

STRUCTURE 194:




TABLE 194: COMPOUNDS 943-954 CORRESPONDING TO STRUCTURE 194

R1	R2	n=	6	7	8	9
H	H		943	944	945	946
H	COOCH ₃		947	948	949	950
-OCH ₂ Ph	COOCH ₃		951	952	953	954

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 196 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R¹ is an H or a -OCH₂Ph and R² is H or COOCH₃. Further preferred embodiments of the compounds corresponding to Structure 196 are set out in Table 196.

STRUCTURE 196:




TABLE 196: COMPOUNDS 955-966 CORRESPONDING TO STRUCTURE 196

R ¹	R ²	n=	6	7	8	9
H	H		955	956	957	958
H	COOCH ₃		959	960	961	962
-OCH ₂ Ph	COOCH ₃		963	964	965	966

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 198 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R¹ is an H or a -OCH₂Ph and R² is H, or COOCH₃. Further preferred embodiments of the compounds corresponding to Structure 198 are set out in Table 198.

STRUCTURE 198:





TABLE 198: COMPOUNDS 967-978 CORRESPONDING TO STRUCTURE 198


R ¹	R ²	n=	6	7	8	9
H	H		967	968	969	970
H	COOCH ₃		971	972	973	974
-OCH ₂ Ph	COOCH ₃		975	976	977	978

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 200 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R¹ is H or a -OCH₂Ph and R² is H or COOCH₃. Further preferred embodiments of the compounds corresponding to Structure 200 are set out in Table 200.

STRUCTURE 200:**TABLE 200: COMPOUNDS 979-990 CORRESPONDING TO STRUCTURE 198**

R1	R2	n=	6	7	8	9
H	H		979	980	981	982
H	COOCH ₃		983	984	985	986
OCH ₂ Ph	COOCH ₃		987	988	989	990

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 202.

STRUCTURE 202:

wherein R₁ is H or COOCH₃. When R₁ is H, the compound of Structure 202 is compound 991. When R₁ is COOCH₃, the compound of Structure 202 is compound 992.

In further embodiments, the compounds of the present invention preferably correspond to compounds of the Structure 204.

STRUCTURE 110:




TABLE 110: SUBSTITUENT GROUPS FOR COMPOUNDS 109-126

R'	n=	4	6	8
I		109	110	111
I*		112	113	114
VII		115	116	117
VII*		118	119	120
VIII		121	122	123
VIII*		124	125	126

In the above Table, R' corresponds to a Fragment as previously defined in Figure 6, E corresponds to a Fragment as previously defined in Figure 8, and n indicates the number of linker groups separating Groups R' and E in the respective compounds. Groups I, VII, VIII each have a benzyl group and Groups I*, VII*, VIII* each have a hydrogen, respectively, in the position designated R in Fragment E of Figure 8.


In further preferred embodiments of the invention herein, the compounds of the present invention correspond to the structures set out in Structure 112. For those compounds that correspond to Structure 112, n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9. In further embodiments, the compounds herein correspond to Structure 112, as further set out in Table 112.

WO 99/36422

92


PCT/US99/00810

STRUCTURE 204:




wherein R₁ is H or COOCH₃. When R₁ is H the compound of Structure 204 is compound 993. When R₁ is COOCH₃ the compound of Structure 206 is 994.


In a particularly preferred embodiment of the invention herein, the present invention comprises compounds of the structures in Table 201 below.

TABLE 201: A GROUPING OF BACTERIAL NAD SYNTHETASE INHIBITOR LEAD COMPOUNDS


13




174




182




190




213




214




228



229



230










270

WO 99/36422

94


PCT/US99/00810




WO 99/36422

95


PCT/US99/00810




765




766



767



768




769


WO 99/36422

96


PCT/US99/00810




832




848



849



850











853

WO 99/36422


97

PCT/US99/00810







884




886




887




889




891



894



906




909


WO 99/36422

99


PCT/US99/00810




917




921




924




936




939




941




942




970




972




973




974










975




976



977



or



The compounds of the invention may be readily synthesized using techniques generally known to synthetic organic chemists. Suitable experimental methods for making and derivatizing aromatic compounds are described, for example, methods for making specific and preferred compounds of the present invention are described in detail in Examples 1 to 4 below.

This invention preferably further provides a method of generating a library comprising at least one bacterial NAD synthetase enzyme inhibitor compound comprising the steps of:

- a. obtaining the crystal structure of a bacterial NAD synthetase enzyme;
- b. identifying one or more sites of catalytic activity on the NAD synthetase enzyme;
- c. identifying the chemical structure of the catalytic sites on the NAD synthetase enzyme;
- d. selecting one or more active molecule compounds that will demonstrate affinity for at least one of the catalytic sites on the NAD synthetase enzyme;
- e. synthesizing one or more dimeric compounds comprised of at least one active molecule wherein the active molecule compound are joined by means of n linker compounds and wherein n is an integer of from 1 to 12, and
- f. screening the one or more compounds for NAD synthetase inhibitor activity.

The library further comprises one or more compounds set forth in Table 201 above. In one embodiment, a library of compounds according to the invention herein preferably includes to compounds of the structures set out in structures 1 to 994 above. Further preferably, the library comprises a compound of Structure 2, still preferably, Structure 4, further preferably, Structure 6. In further preferred embodiments, the library comprises at least one compound of Structure 8, Structure 10, Structure 12, Structure 16 or Structure 18.

In another preferred embodiment of the invention herein, the one or more dimeric compounds comprise at least two active molecules. Still preferably, the active molecules are the same. Alternatively, it is preferable that the active molecules are different.

The invention further provides a software program that predicts the binding affinities of molecules to proteins utilized in the active molecule selection step. Further preferably, a software program that evaluates the chemical and geometric complementarity between a small molecule and macromolecular binding site is utilized in the active molecule selection step.

In yet another preferred embodiment, the compounds are synthesized utilizing a rapid, solution phase parallel synthesis and wherein the compounds are generated in a combinatorial fashion.

In a preferred embodiment, the invention provides a method of treating or preventing a microbial infection in a mammal comprising administering to the mammal a treatment effective or treatment preventive amount of a bacterial NAD synthetase enzyme inhibitor compound. In a particularly preferred embodiment, the compound administered in the method is a compound as set out previously in Table 201. In another embodiment, invention herein preferably includes to compounds 1 to 994 above. Further preferably, the compound administered comprises at least one compound of Structure 2, still preferably, Structure 4, further preferably, Structure 6. In further preferred embodiments, the compounds administered in the method comprise compounds of Structure 8, Structure 10, Structure 12, Structure 16 or Structure 18.

In preferred embodiment, the invention provides administering a broad spectrum antibiotic to a mammal in need of such treatment or prevention. In a further preferred embodiment, the microbial infection is a bacterial infection. In yet another embodiment of the invention, the bacterial infection is caused by a bacterium that is a gram negative or gram positive bacteria. The bacterial infection may preferably be caused by an antibiotic resistant strain of bacteria.

Further provided by the invention herein is preferably a method of killing a prokaryote with an amount of prokaryotic NAD synthetase enzyme inhibitor compound to reduce or eliminate the production of NAD whereby the prokaryote is killed. A method of decreasing prokaryotic growth, comprising contacting the prokaryote with an amount of a prokaryotic NAD synthetase enzyme inhibitor effective to reduce or eliminate the production of NAD whereby prokaryotic growth is decreased is also provided. In the method of killing a prokaryote, as well as in the method of decreasing prokaryotic growth, the compound comprises one or more compounds of Table 201. Still preferably, the invention comprises one or more of compounds 1 to 994 above. Further preferably, the compound administered is a compound of Structure 2, still preferably, a compound of Structure 4, further preferably, Structure 6. In further preferred embodiments, the compounds administered in the methods compounds of Structure 8, Structure 10, Structure 12, Structure 16 or Structure 18.

In the method of killing a prokaryote, as well as in the method of decreasing prokaryotic growth, the prokaryote is a bacterium. Further preferably, the bacterium is a gram negative or a gram positive bacteria. Still preferably, the prokaryote is an antibiotic resistant strain of bacteria.

Also in the method of killing a prokaryote, as well as in the method of decreasing prokaryotic growth, the NAD synthetase enzyme inhibitor is a compound that selectively binds with catalytic sites or subsites on a bacterial NAD synthetase enzyme to reduce or eliminate the production of NAD by the bacteria.

In the methods discussed above, the compound is preferably administered by oral, rectal, intramuscularly, intravenous, intravesicular or topical means of administration. The compounds of this invention can be administered to a cell of a subject either *in vivo* or *ex vivo*. For administration to a cell of the subject *in vivo*, as well as for administration to the subject, the compounds of this invention can be administered orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, subcutaneous

injection, transdermally, extracorporeally, topically, mucosally or the like.

Depending on the intended mode of administration, the compounds of the present invention can be in pharmaceutical compositions in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, lotions, creams, gels, or the like, preferably in unit dosage form suitable for single administration of a precise dosage. The compositions will include, as noted above, an effective amount of the selected composition, possibly in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc.

Parenteral administration of the compounds of the present invention, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. As used herein, "parenteral administration" includes intradermal, subcutaneous, intramuscular, intraperitoneal, intravenous and intratracheal routes. One approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained. *See e.g.*, U.S. Patent No. 3,610,795, which is incorporated by reference herein. These compounds can be present in a pharmaceutically acceptable carrier, which can also include a suitable adjuvant. By "pharmaceutically acceptable," it is meant a material that is not biologically or otherwise undesirable, *i.e.*, the material may be administered to an individual along with the selected compound without causing substantial deleterious biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained.

Routes of administration for the compounds herein are preferably in a suitable and pharmacologically acceptable formulation. When administered to a human or an animal subject, the bacterial NAD synthetase enzyme inhibitor compounds of the libraries herein are preferably presented to animals or humans orally, rectally, intramuscularly, intravenously, intravesicularly or topically (including inhalation). The dosage preferably

comprises between about 0.1 to about 15g per day and wherein the dosage is administered from about 1 to about 4 times per day. The preferred dosage may also comprise between 0.001 and 1 g per day, still preferably about 0.01, 0.05, 0.1, and 0.25, 0.5, 0.75 and 1.0 g per day. Further preferably, the dosage may be administered in an amount of about 1, 2.5, 5.0, 7.5, 10.0, 12.5 and 15.0 g per day. The dosage may be administered at a still preferable rate of about 1, 2, 3, 4 or more times per day. Further, in some circumstances, it may be preferable to administer the compound of the invention continuously, as with, for example, intravenous administration. The exact amount of the compound required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the particular compound used, its mode of administration and the like. Thus, it is not possible to specify an exact amount for every compound. However, an appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein.

If *ex vivo* methods are employed, cells or tissues can be removed and maintained outside the subject's body according to standard protocols well known in the art. The compounds of this invention can be introduced into the cells via known mechanisms for uptake of small molecules into cells (e.g., phagocytosis, pulsing onto class I MHC-expressing cells, liposomes, etc.). The cells can then be infused (e.g., in a pharmaceutically acceptable carrier) or transplanted back into the subject per standard methods for the cell or tissue type. Standard methods are known for transplantation or infusion of various cells into a subject.

It is further provided a method of disinfecting a material contaminated by a microbe, comprising contacting a contaminated material with a bacterial NAD synthetase enzyme inhibitor compound in an amount sufficient to kill or deactivate the microbe. In yet another embodiment, the compound utilized for contacting comprises one or more compounds of Table 201. The compounds utilized for contacting may also comprise one or more of compounds 1 to 994. Further preferably, the compound utilized for contacting is a compound of Structure 2, still preferably, a compound of Structure 4, further preferably, Structure 6. In further preferred embodiments, the compounds utilized for

contacting in the method comprise compounds of Structure 8, Structure 10, Structure 12, Structure 16 or Structure 18.

In yet a further embodiment of the invention herein, the compounds of the present invention are effective as disinfectant materials for, for example, hard or soft surfaces, fabrics, and other contaminated materials such as those in hospitals, households, schools, nurseries, and any other location. In yet another embodiment, the invention provides a method for disinfecting comprising contacting a bacterial contaminated material with a bacterial NAD synthetase enzyme inhibitor compound.

In a further aspect of the invention, an *in vitro* "one-at-a-time" method of screening compounds for bacterial NAD synthetase enzyme inhibitory activity is provided. In a preferred embodiment, this *in vitro* method of screening compounds for such activity comprises the steps of preparing a solution comprising pure bacterial NAD synthetase enzyme, contacting the solution with the compounds set out herein, and determining the rate of the enzyme-catalyzed reaction. Preferably, measurement of the rate of enzyme-catalyzed reaction comprises a measure of NAD synthetase inhibitory activity. In a further embodiment, the rate of enzyme-catalyzed reaction comprises a measure of antibacterial activity. In a still further embodiment, the rate of enzyme-catalyzed reaction corresponds to a measure of antimicrobial activity.

Preferably, the method of preparing the bacterial enzyme solution for use in the *in vitro* screening method comprises utilizing molecular biological methods to over-express bacterial NAD synthetase enzyme, for example from *B. subtilis*, in *E. coli*. One of skill in the art will recognize techniques useful for such a process. A particularly preferable method comprises: a) cloning the Out B gene encoding NAD synthetase enzyme and over-expressing the gene in *E. coli*; b) purifying the cloned and over-expressed gene by ion-exchange; c) purifying further the enzyme material from step b using ion-exchange methods; d) further purifying the material from step c using size exclusion chromatography wherein the bacterial NAD synthetase enzyme is essentially pure; and e) preparing an assay solution in quantities of about 10 to 15 mg pure bacterial NAD

synthetase enzyme per liter of fermentation broth. As used herein, "essentially pure" means greater than about 90% purity, more preferably, greater than about 95% purity and, still more preferably, greater than about 99% purity.

In one embodiment of the *in vitro* screening method, the following procedure is utilized to measure the rate of enzyme catalyzed reaction. A solution of HEPPS, pH 8.5, with KCl is prepared containing the following species: ATP, NaAD, $MgCl_2$, NH_4Cl , ADH, and ETOH. A stock solution of test inhibitors is then prepared by dissolving solid samples into 100% DMSO. The test compound stock solution is then added to the mixture to give the final test compound concentrations. NAD synthetase enzyme solution is added, the mixture is mixed three times, and the absorbance at 340 nm is then monitored kinetically using an UV-Vis spectrophotometer. The initial kinetics trace after enzyme addition is then fit to a straight line using linear regression, with this rate is then compared to that of a control containing no inhibitor, using the following formula to calculate % Inhibition: $\{(V_0 - V)/V_0\} * 100\%$, where V_0 is the rate of the reaction with no test compound present and V is the rate of the reaction with test the test compound added. Each compound is tested in triplicate, and the resulting values for % inhibition were averaged to give the listed value. IC_{50} (concentration needed to inhibit 50% of the test bacteria) values were obtained for select compounds by assaying six different concentrations of test compound, in triplicate, at concentrations between 0.0 and 2.0 mM, and plotting the resulting % inhibition values against the -LOG of the test compound dose to reveal the concentration at which 50% inhibition is observed.

Preferably, the *in vitro* method can also be adapted to allow screening for compounds with bacterial NAD synthetase enzyme inhibitory activity in other forms of bacteria, as well as other types of microbes. For example, the above-described procedure can be adapted to screen for inhibitory activity in at least the following bacteria types:

WO 99/36422

109

PCT/US99/00810

BACTERIUM	STRAIN
<i>Escherichia coli</i> K-12	MG1655 (CGSC#6300)
<i>Escherichia coli</i> K-12	W3110 (CGSC#4474)
<i>Salmonella typhimurium</i>	LT2 TT366
<i>Streptococcus pneumonia</i>	D39
<i>Streptococcus pneumoniae</i>	WU2
<i>Bacillus subtilis</i>	A700

In a further embodiment of the *in vitro* screening method, the method can be used to screen existing compounds *e.g.*, commercially available compounds, such as 5-nitroindole and N-methyl nicotinic acid. One of skill in the art will recognize the manner in which the designing and screening methods herein can be utilized to identify commercially available compounds, such as the previous non-exhaustive list, that will exhibit NAD synthetase enzyme inhibitory activity, both in bacteria and other microbes.


In order to test a library of NAD synthetase enzyme inhibitor compounds, such as those of the present invention, it is particularly preferable to utilize a method of rapid (high throughput) screening. To this end, the potential inhibitory activity of the library of synthetic compounds in one embodiment is assessed *via* a coupled enzymatic assay. The coupled assay involves two steps as summarized below.

WO 99/36422


110

PCT/US99/00810

Step 1



Step 2



In order to rapidly measure the inhibitory activities of the compounds in the library, the invention provides a high through-put screening system (HTS system). The HTS system preferably utilizes an integrated robotic system that coordinates the functions of a liquid handler and a spectrophotometer. The robotic station is preferably responsible for the movement of all hardware and the integration of multiple stations on the worksurface. The liquid handler is preferably programmed to perform all phases of liquid dispensing and mixing. The spectrophotometer is preferably equipped to monitor absorbance in a 96-well plate format.

In one embodiment, the assay is designed for a 96-well plate format reaction buffer containing HEPPS buffer, pH 8.5, MgCl_2 , NH_4Cl , KCL, NaAD, n-Octyl-D-Glucopyranoside, ethanol, NAD synthetase, and yeast alcohol dehydrogenase. At the next stage, the liquid handler dispenses DMSO (with or without inhibitor) into the reaction well. The liquid handler mixes these components utilizing a predefined mixing program. The reaction is initiated by the addition of a solution of ATP dissolved in buffer. The reaction is monitored by measuring the increase in absorbance at 340nm. The linear portion of the reaction is monitored for a period of time. The initial velocity is determined using the software supplied with the spectrophotometer.

The compounds of the library herein are supplied as a stock with a concentration dissolved in 100% DMSO. An initial screen is conducted on all compounds using a 2 or 3

concentration screen. The 2 panel screen used concentrations of 0.2mM and 0.1mM for the compounds. The 3 panel screen used concentrations of 0.2mM, 0.1mM, and 0.05mM. From the initial screen, "lead compounds" *e.g.*, those compounds which demonstrated the greatest inhibitory capacity, are then preferably subjected to a wider screen of concentrations (0.1mM to 0.001mM) to determine the apparent IC-50 values for each compound.

In still a further preferred embodiment of the invention herein, the high throughput method is utilized to screen commercially available compounds for bacterial NAD synthetase enzyme inhibitory activity. In an additional embodiment, the NAD synthetase enzyme inhibitor compounds are tested as inhibitors of bacterial growth against a variety of bacteria types.

In a further embodiment of the invention, compounds within the libraries of NAD synthetase inhibitor compounds are evaluated for antibacterial and antimicrobial activity. In one embodiment, compounds are preferably evaluated for their potential to inhibit the growth of *Bacillus subtilis*, *Pseudomonas aeruginosa*, and *Staphylococcus epidermitis*. The inhibitors are preferably initially screened in duplicate at one concentration. The test inhibitor compounds are prepared by dissolving the solid samples in DMSO. Aliquots from the inhibitor stocks are placed in sterile 96-well plates by the liquid handler discussed previously. Cultures of *B. subtilis*, *P. aeruginosa* and *S. epidermitis* are prepared in liquid broth (LB) media and incubated in an orbital shaker overnight. Dilutions (with LB media) of the overnight cultures are added to the 96-well plates containing the inhibitors. The plates are incubated and the absorbance measured at 595nm in a plate reader.

In this embodiment of the invention, a diluted overnight culture without inhibitors serves as one of three controls in the experiments. A positive control, which includes an identical concentration of the drug Tobramycin as the inhibitors being tested, and a DMSO control are also performed during each inhibitor screen. The DMSO control was included for comparison with the control that contained no inhibitors.

Percent inhibition of each inhibitor was calculated by the following formula:

$\{(A_D - A_I) / A_D\} * 100$; where A_D = the absorbance at 595nm of the DMSO control and A_I = the absorbance of the inhibitor at 595nm.

In a further embodiment, dose responses are performed on the compounds that inhibited greater than 85% in the initial screen. The dose responses consisted of 5 different concentrations (from 100 mM – 0.1 mM) of each inhibitor and the positive control Tobramycin. The cultures are prepared and grown in the same manner as the inhibitor screens and the same controls were included. The absorbance is measured every hour and a half during the six hours of growth. Percent inhibitions are calculated again for each concentration tested. The lowest concentration that resulted in an 85% inhibition or higher is termed the Minimum Inhibitory Concentration that inhibited bacterial growth 85% (MIC_{85}).

When a NAD synthetase enzyme inhibitor compound of a library herein are to be administered to a humans or an animal *e.g.* a mammal, it is preferable that the compounds show little or no toxicity to the patient. Therefore, in one embodiment of the invention herein, the toxicities of the NAD-synthetase enzyme inhibitors are evaluated using human epithelial cells as set out in Example 10 below.

EXAMPLES

The following examples are set forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compositions and methods claimed herein are made and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers (*e.g.*, amounts, temperature, etc.) but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C or is at room temperature, and pressure is at or near atmospheric.

EXAMPLE 1: EXPERIMENTAL PROCEDURE FOR PREPARING COMPOUNDS SINGLY IN SCHEME 3 (N=6).

The following Example 1 describes one embodiment of the invention herein for compounds prepared according to the synthetic pathway set out in Scheme 3, described previously. For this particular Example, the linker length *e.g.*, *n*, is equal to 6. Compounds prepared according this embodiment were prepared, individually, *i.e.*, not using parallel solution phase synthesis methods. One of skill in the art will readily recognize the manner in which the following Example may be varied to obtain the linker lengths within the scope of the present invention.

A. Alkylation of 5-nitroindole with 6-bromohexyl acetate. A solution of 5-nitroindole (1.00 g, 6.22 mmol) in DME (2.0 mL) was added dropwise using an addition funnel to the suspension of NaH (0.24 g, 0.01 mmol in 2.0 mL DME), previously washed with DME (3 X 3.0 mL). The sides of the addition funnel were rinsed with an additional 2.0 mL of DME. During the addition, an instantaneous gas evolution occurred. The reaction flask was then immersed into a preheated oil bath at 80°C and allowed to gently reflux for 15 minutes. The flask was then cooled to ambient temperature and a solution of 5-bromohexyl acetate (1.39 g, 6.22 mmol) dissolved in DME (2.0 mL) was added dropwise using the addition funnel. The sides of the funnel were washed with an additional portion of DME (2.0mL). The reaction flask was then immersed into a preheated oil bath set at 80°C and allowed to reflux for 18 hours. Workup consisted of quenching the reaction using saturated NH₄Cl (25 mL) and extracting the aqueous layer with ethyl acetate (4 X 25 mL). The organic layers were combined, dried over anhydrous Na₂SO₄, filtered, and evaporated to dryness under reduced pressure. The product was then purified by flash chromatography on silica gel using hexane-acetone (9:3) to afford the product (0.39 g) and deacetylated product (1.11 g, for a combined yield 91.2%). The acetylated product was isolated as a yellow colored viscous oil.

The acetylated product from Step A was analyzed, yielding the following

WO 99/36422

114

PCT/US99/00810

confirmatory data: IR (KBr) 1735 (C=O) cm^{-1} ; ^1H -NMR (300 MHz) δ 8.59 (d, 1H, H-4, $J = 2.2$ Hz), 8.12 (dd, 1H, H-6, $J = 9.1, 2.2$ Hz), 7.35 (d, 1H, H-7, $J = 9.1$ Hz), 7.26 (d, 1H, H-2, $J = 3.2$ Hz), 6.68 (d, 1H, H-3, $J = 3.2$ Hz); 4.17 (t, 2H, N-CH₂, $J = 7.1$ Hz), 4.04 (t, 2H, O-CH₂, $J = 6.6$ Hz), 2.03 (s, 3H, acetate), 1.90 (quintet, 2H, N-CH₂-CH₂, 2H, $J = 7.2, 7.5$ Hz), 1.61 (quintet, 2H, O-CH₂-CH₂, $J = 6.8, 7.1$ Hz), 1.37 (m, 4H, N-CH₂-CH₂-CH₂); ^{13}C -NMR (75 MHz) δ 170.8 (acetate), 141.0 (C-5), 138.5, 130.7, 127.4, 117.8, 116.7, 108.9, 103.6, 63.9 (O-CH₂), 46.4 (N-CH₂), 29.8, 28.1, 26.2 (CH₃, acetate), 25.3, 20.7; MS (ES, m/z) 327 amu ($M + \text{Na}^+$) (100), 305 ($M + \text{H}^+$); Anal. Calcd. for C₁₆H₂₀N₂O₄: C, 63.14; H, 6.65; N, 9.20. Found: C, 63.09; H, 6.61; N, 9.14.

B. Transesterification of 6-[N-(5-nitroindolyl)]hexyl acetate. The indole acetate from Step A (1.07 g, 3.52 mmol) was dissolved in methanol (25 mL) and anhydrous K₂CO₃ (1.46 g, 10.57 mmol) was added. Water (8.0 mL) was then added to this suspension. The contents in the reaction flask were stirred for 20 hours at ambient temperature. The reaction was worked up by evaporation of the solvent under reduced pressure. The residue was then taken up in water (30 mL) and extracted successively with ethyl acetate (2 X 30 mL) and ether (3 X 30 mL). The combined extracts were dried over anhydrous Na₂SO₄, filtered, and evaporated under reduced pressure. The crude product was purified using flash chromatography on silica gel using ethyl acetate: hexane (6:4) to give Compound 862 as a pale yellow solid (0.85 g, 91.6%).

The material from Step B was analyzed yielding the following confirmatory data: m.p. 78.3-78.7 °C. IR (KBr) 3733 (OH) cm^{-1} ; ^1H -NMR (300 MHz) δ 8.60 (d, 1H, H-4, $J = 2.2$ Hz), 8.12 (dd, 1H, H-6, $J = 9.1, 2.2$ Hz), 7.36 (d, 1H, H-7, $J = 9.1$ Hz), 7.25 (d, 1H, H-2, $J = 3.3$ Hz), 6.68 (d, 1H, H-3, $J = 3.3$ Hz), 4.18 (t, 2H, N-CH₂, $J = 7.1$ Hz), 3.63 (q, 2H, O-CH₂, $J = 6.1, 11.6$ Hz), 1.88 (quintet, 2H, N-CH₂-CH₂, 2H, $J = 7.2, 7.5$ Hz), 1.56 (quintet, 2H, O-CH₂-CH₂, $J = 6.8, 7.1$ Hz), 1.40 (m, 2H, N-CH₂-CH₂-CH₂), 1.25 (t 1H, OH, $J = 5.4$ Hz); ^{13}C -NMR (75 MHz) 141.0 (C-5), 138.5, 130.9, 127.4, 118.0, 116.8, 109.0, 103.7, 62.4 (O-CH₂), 46.6 (N-CH₂), 32.3, 29.9, 26.5, 25.2; MS (ES, m/z) 263 amu ($M + \text{H}^+$) (100), 280 ($M + \text{NH}_4^+$), 285 ($M + \text{Na}^+$); Anal. Calcd. for C₁₄H₁₈N₂O₃: C, 64.10; H, 6.91; N, 10.68. Found: C, 64.21; H, 6.91; N, 10.69.

C. Esterification of 6-[N-(5-nitroindolyl)]hexan-1-ol using nicotinic acid.

The alcohol from Step B (0.350 g, 1.37 mmol), nicotinic acid (0.210 g, 1.69 mmol), DCC (0.310 g, 1.51 mmol) and DMAP (17.0 mg, 0.140 mmol) were dissolved in dichloromethane (12.0 mL). The suspension was stirred at ambient temperature and monitored by TLC. After 20 hours the reaction was worked up by filtering off the white solid, washing the filter with dichloromethane (15.0 mL), and washing the organic filtrate with brine (3 X 25 mL). The filtrate was then dried over anhydrous Na_2SO_4 and evaporated to dryness. Purification of the product was done by flash chromatography on silica gel using ethyl acetate-hexane (6:4) to give the product as a yellow colored solid (0.45 g, 90%).

The material from Step C was analyzed yielding the following confirmatory data: m.p. °C; IR (KBr) 1717 (C=O) cm^{-1} ; ^1H -NMR (300 MHz) 89.13 (d, 1H, H-2', J = 1.9 Hz), 8.71 (dd, 1H, H-6', J = 4.8, 1.5, Hz), 8.51 (d, 1H, H-4, J = 2.2 Hz), 8.20 (dt, 1H, H-4', J = 2.0, 6.0 Hz), 8.03 (dd, 1H, H-6, J = 9.1, 2.2 Hz), 7.32 (dd, 1H, H-5', J = 4.8, 1.1 Hz), 7.29 (d, 1H, H-7, J = 9.1 Hz), 7.17 (d, 1H, H-2, J = 3.2 Hz), 6.60 (d, 1H, H-3, J = 3.2 Hz); 4.25 (t, 2H, N-CH₂, J = 6.5 Hz), 4.11 (t, 2H, O-CH₂, J = 7.0 Hz), 1.83 (quintet, 2H, N-CH₂-CH₂, 2H, J = 7.2, 7.5 Hz), 1.70 (quintet, 2H, O-CH₂-CH₂, J = 6.8, 7.1 Hz), 1.36 (m, 2H, N-CH₂-CH₂-CH₂); ^{13}C -NMR (75 MHz) 8164.9 (nicotinate C=O), 153.1 (C-2'), 150.5 (C-6'), 141.0 (C-5), 138.4 (C-7), 136.7 (C4'), 130.8 (C-2), 127.3 (C-3'), 125.8 (C-3), 123.1 (C-5'), 117.8 and 116.8 (C-4,6), 108.9 (C-7), 103.6 (C-3), 64.9 (O-CH₂), 46.5 (N-CH₂), 29.7 (O-CH₂-CH₂), 28.2 (N-CH₂-CH₂), 26.3 (O-CH₂-CH₂-CH₂), 25.4; MS (ES, m/z) 368 amu ($\text{M} + \text{H}^+$) (100).

D. N-Methylation of 6-[N-(5-nitroindolyl)]hexyl nicotinate. The ester from Step C (0.104 g, 0.294 mmol) was mixed with iodomethane (0.036 mL, 0.589 mmol). The reaction was heated in an oil bath to 60°C overnight (18 hours). The work-up consisted of evaporating the solvent under reduced pressure then recrystallization of the residue using 2-propanol to give a yellow colored solid (0.120 g, 82.3%).

WO 99/36422

116

PCT/US99/00810

The material from Step D was analyzed yielding the following confirmatory data: m.p. 109.1-109.9°C; IR (KBr) 1717 (C=O) cm^{-1} ; $^1\text{H-NMR}$ (300 MHz) δ 9.42 (sm 1H, H-2'), 9.11 (d, 1H, H-6', $J = 6.1$ Hz), 8.63 (d, 1H, H-4', $J = 8$ Hz), 8.50 (d, 1H, H-4, $J = 2.0$ Hz), 8.19 (dt, 1H, H-6, $J = 6.3, 7.9$ Hz), 8.01 (dd, 1H, H-5', $J = 2.3, 9.1$ Hz), 7.56 (d, 1H, H-7, $J = 9.1$ Hz), 7.50 (d, 1H, H-2, $J = 3.1$ Hz); 6.69 (d, 1H, H-3, $J = 330$ Hz); 4.50 (s, 3H, N^+-CH_3); 4.42 (t, 2H, $\text{N}-\text{CH}_2$, $J = 6.4$ Hz), 4.31 (t, 2H, $\text{O}-\text{CH}_2$, $J = 6.9$ Hz), 1.95 (quintet, 2H, $\text{N}-\text{CH}_2-\text{CH}_2$, 2H, $J = 7.2, 7.5$ Hz), 1.84 (quintet, 2H, $\text{O}-\text{CH}_2-\text{CH}_2$, $J = 6.8, 7.1$ Hz), 1.46 (m, 2H, $\text{N}-\text{CH}_2-\text{CH}_2-\text{CH}_2$); $^{13}\text{C-NMR}$ (75 MHz) δ 162.7 (nicotinate C=O), 149.8 (C-), 148.2 (C-), 142.7 (C-5), 140.5 (C-7), 133.2 (C-4'), 132.2 (C-2), 129.4 (C-3'), 129.3 (C-3), 118.8 and 117.8 (C-4,6), 111.1 (C-7), 104.8 (C-3), 67.7 ($\text{O}-\text{CH}_2$), 49.6 (N^+-CH_3), 47.5 ($\text{N}-\text{CH}_2$), 30.9 ($\text{O}-\text{CH}_2-\text{CH}_2$), 29.2 ($\text{N}-\text{CH}_2-\text{CH}_2$), 24.2 ($\text{O}-\text{CH}_2\text{CH}_2-\text{CH}_2$); MS (ES, m/z) 368 amu (M^+) (100), 127 (T^+) (100); Anal. Calcd. for $\text{C}_{20}\text{H}_{24}\text{N}_3\text{O}_4\text{I}$: C, 48.50; H, 4.48; N, 8.48. Found: C, 48.36; H, 4.46; N, 8.34.

The synthetic procedures described below with respect to Schemes 4-6 were developed for use as combinatorial chemical methods using, for example, parallel solution phase synthesis techniques. One of skill in the art would recognize the meaning of these terms.

EXAMPLE 2: GENERAL EXPERIMENTAL PROCEDURES USED FOR PREPARING SOLUTION PHASE COMBINATORIAL LIBRARIES DESCRIBED IN SCHEME 4.

The following Example 2 describes a preferred embodiment of the invention herein for compounds prepared according to the synthetic pathway set out in Scheme 4, described previously. One of skill in the art will recognize that many possible variations on this embodiment exist that will not result in deviation from the novel and unobvious aspects of the invention.

WO 99/36422

117

PCT/US99/00810

A. Alkylation of 5-nitroindole with the bromoalkyl acetate and conversion of the indole alkyl acetate to the alcohol. A solution of 5-nitroindole (1g, 6.17⁴mmol) in DMF (10.0mL) was prepared in 4 dram vials (size 28 X 57mm). This solution was then transferred to a second 4 dram vial containing a suspension of NaH (0.22g, 9.25mmol) in DMF (8.0mL). During the addition, an instantaneous gas evolution was observed and a nitrogen inlet was used to prevent gas pressure build up. The robotic synthesizer was then used to dispense 3.0mL of the indole sodium salt solution into 5 culture tubes (16 X 125mm) in a synthesizer block. The bromoalkyl acetate (1.36mmol) was dissolved in DMF (8mL total volume, 1.36M solution) in a 4 dram vial, 1mL of this solution was transferred into designated test tubes using the robotic synthesizer. After allowing the reaction to block shake for 15 hours at ambient temperature, tris(2-aminoethyl)amine resin (0.15g, 0.329mmol) was added and the reaction was shaken for 12 hours with heating at 55 °C. The resin was filtered using 3cc syringes each with a cotton plug and connected to a 24-port manifold and a water aspirator provided vacuum suction. The filtrate was collected in culture tubes (16 X 125mm) and the resin was washed using MeOH (3.0mL). Prior to placing the tubes in the reaction block a catalytic amount of NaH (10-12mg) was added to each tube and allowed to shake at ambient temperature for 12 hours. Work-up consisted of adding ethyl acetate (4.0mL) and water (3.0mL) to each sample, shaking and removing the organic layer then subsequently washing the organic layer using brine (2 X 3.0mL). The organic layer was dried over anhydrous Na₂SO₄, filtered *vide supra*, and the solvent was transferred to 4 dram vials evaporated using a speed vac to give the alcohol as a solid residue whose weight range was from 100mg to 226mg.

B. Formation of the indole alkyl ester. The alcohol (0.100g, 0.381mmol) was purged with argon and dissolved in dichloromethane (5.0mL), 1mL aliquots were transferred to 5 culture tubes (13 X 100mm), triethylamine (106μL) was added to each tube, and the tubes were then capped and placed in an ice bath for 15 minutes. Methanesulfonyl chloride (38μL) was then added to each vial, then shaken by hand for 10 seconds and placed in the refrigerator at 1.8°C for 12 hours. Each sample was worked up by the addition of ethyl acetate (5mL), and washed with water (2 X 3mL) and brine (3 mL). The organic layer was dried by passing it through a B-D 3cc syringe containing

WO 99/36422

118

PCT/US99/00810

anhydrous Na_2SO_4 using the manifold described above and collecting the filtrate in culture test tubes (16 X 125mm). The solvent was then transferred to 4 dram vials and evaporated *vide supra* to give residue weights of 0.128g to 0.159g. The residue in the vials (0.128g, 0.498mmol) was then purged with argon and dissolved in anhydrous DMF (3mL). This solution was then transferred to culture tubes (13 X 100mm) containing 2 equiv. of nicotinic acid (457mg, 1.72mmol) and 1 equiv. K_2CO_3 (120mg, 0.858mmol) in DMF (5mL). The tubes were shaken and heated in a digitally controlled heating block at 50°C for 15 hours. The reactions were worked up by pouring the contents of the tubes into 4 dram vials containing ethyl acetate (5mL), and this was washed with water (2 X 5mL) and brine (2 X 5mL). The organic layer was dried by passing it through a 3cc syringe containing anhydrous Na_2SO_4 *vide supra*. The filtrate was collected into culture tubes (16 X 125mm) and transferred to 4 dram vials and evaporated under reduced pressure to give the ester as a residue whose weight range was 27mg to 59mg.

C. **N-Methylation.** The ester from Step B above, (32mg, 0.108mmol) was transferred into culture tubes (13 X 100mm) and dissolved in DME (1.5mL) then followed by the addition of 5 equiv. of iodomethane (36 μ L, 0.077mmol). The tubes were shaken and heated in a digital heating block at 50°C for 12 hours. Work-up consisted of transferring the contents of the tubes into 1 dram vials and evaporating the solvent under reduced pressure to give the *N*-methyl derivative as a solid product (weight range 17mg to 39mg) which was isolated by filtration.

EXAMPLE 3: GENERAL EXPERIMENTAL PROCEDURES USED FOR PREPARING SOLUTION PHASE COMBINATORIAL LIBRARIES DESCRIBED IN SCHEME 5

The following Example 3 describes a preferred embodiment of the invention herein for compounds prepared according to the synthetic pathway set out in Scheme 5, described previously. One of skill in the art will recognize that many possible variations on this embodiment exist that will not result in deviation from the novel and unobvious aspects of the invention

A. **Methyl and benzyl esters of indole carboxylates.** Potassium carbonate (0.55 eq) was added to indole carboxylic acid (6.1 mmol) stirred in dry DMF (10 mL) at r.t. After 10 min., the alkyl iodide (benzyl or methyl) (1.1 eq) was added. This was worked up after 24 hours in 30 mL centrifuge tubes by taking the RM, diluting in EtOAc (25 mL), and washing with NaHCO₃ (2x10 mL), H₂O (2x10 mL), and brine (10 mL). The resulting solution was dried (Na₂SO₄), evaporated to dryness, and recrystallized from EtOAc-hexanes.

B. **N-Alkylation of indole esters with bromoalkyl acetates.** NaH (2.93 mmol) was washed with dry DMF (4 mL), re-suspended in dry DMF (7 mL) and cooled at 0 °C under a nitrogen atmosphere. A solution of the dry indolecarboxylate ester (1.95 mmol) in dry DMF (7 mL) was slowly added, dropwise, to the NaH suspensions contained in 20 mL vials. This was under mixed on an orbital shaker and warmed to r.t. After 1 hour, 2 mL of each 14 mL solution was dispensed into 7 100x13 cultures tubes (7x7=49 tubes containing 0.285 mmol each).

For each linker size (e.g., n=5 to 9), the bromoalcohol acetate (7.7 eq) was diluted to 3.5 mL with dry DMF. A portion of this solution (0.5 mL, 1.1 eq., 0.313 mmol) was slowly added to the reaction mixture containing the indole anions. The mixtures were shaken at r.t. for 15 hours. TLC for product revealed R_f=0.3 to 0.7 (3:7 EtOAc-hexanes).

Each culture tube was treated with a polymer supported trapping resin, tris(2-aminoethyl)amine (0.16 eq, 0.046 mmol), and the tubes were shaken at 50°C for 6.5 hours. The mixture was filtered through cotton in 1 mL syringes using a 24 port manifold, the filter was washed with dry MeOH (2 mL), and the filtrate was collected and concentrated in 100x13 mm culture tubes to provide the product.

C. **Formation of the alcohol from the indolealkyl acetate.** For the methyl esters, a MeOH-MeONa solution was prepared as follows: NaH (2.85 mmol) was washed with dry DMF (2x2mL), suspended in dry DMF (2mL), cooled at 0°C, and dry MeOH (8

WO 99/36422

120

PCT/US99/00810

mL) was slowly added. The resulting mixture was then shaken for 30 min at r.t. A portion (0.2 mL, 0.2 eq) of this solution was dispensed to each tube containing the indolealkyl acetate, and the resulting mixture was shaken at r.t. for 16 hours. The mixtures were diluted with EtOAc (6 mL) and extracted with H₂O (5 mL) in 30 mL centrifuge tubes. The aqueous washes were re-extracted with EtOAc (3x2 mL). The combined EtOAc layers were washed with H₂O (2x4 mL) and brine (2 mL), dried (Na₂SO₄), and filtered into 20 mL vials. The solvent was removed in a speed-vac under reduced pressure to provide the product: R_f=0.05 to 0.35 (3:7 EtOAc-hexanes).

For the benzyl esters, a 1 N NaOH solution (5 eq) was added to the indolealkyl acetate and the mixture was shaken for 2 days at r.t. The mixtures were diluted with EtOAc (6 mL) and extracted with H₂O (5 mL) in 30 mL centrifuge tubes. The aqueous washes were re-extracted with EtOAc (3x2 mL). The combined EtOAc layers were washed with H₂O (2x4 mL) and brine (2 mL), dried (Na₂SO₄), and filtered into 20 mL vials. The solvent was removed in a speed-vac under reduced pressure to provide the product: R_f=0.05 to 0.35 (3:7 EtOAc-hexanes).

D. Coupling of the indole alcohol with aromatic amines. To the alcohol (0.1 mmol) in dry CH₂Cl₂ (1 mL) was added the aromatic amine (10 eq. pyridine, quinoline, isoquinoline, or methyl nicotinate; 4 eq. benzyl 3-quinolinecarboxylate). The resulting mixture was cooled at 0 °C and trifluoromethanesulfonic anhydride (1.3 eq.) was slowly added. The mixture was shaken for 2 hours at 0 °C, and then at r.t. for 14 hours. The reaction mixture was diluted with EtOAc (3mL) and washed with 1 N HCl (3x1 mL), water (2x1 mL) and brine (1 mL). The solution was dried (Na₂SO₄) and concentrated on the speed-vac under reduced pressure to provide the product.

E. Conversion of the methyl and benzyl indolecarboxylates to the carboxylic acids. For methyl esters, the methyl indolecarboxylate (0.1 mmol) was solubilized in MeOH-H₂O (3:1, 0.8 mL) and 1 N NaOH (7 eq for diesters, 5 eq for monoesters) was added. The reaction mixture was then heated at 45°C on an orbital platform shaker for 14 hours. The solution was evaporated to dryness on a speed-vac and

the residue dissolved in DMSO for biological evaluation.

Benzyl esters (0.04-0.09 mmol) were solubilized in a mixture of MeOH-CH₂Cl₂-H₂O (8:1:1) (1.5 mL) were hydrogenated using Pd/C (10%) (50 mg) in 100x13 mm culture tubes containing 10 glass beads (diameter=3 mm) under 40 psi H₂ at r.t. for 8 hours. Under these conditons, 14 tubes could be placed in a 500 mL PAR apparatus bottle. Filtration through a celite pad and concentration on a speed-vac under reduced pressure afforded the carboxylic acids. Products containing the reduced pyridinium ring were also produced.

EXAMPLE 4: GENERAL EXPERIMENTAL PROCEDURES USED FOR PREPARING SOLUTION PHASE COMBINATORIAL LIBRARIES DESCRIBED IN SCHEME 6

The following Example 4 describes a preferred embodiment of the invention herein for compounds prepared according to the synthetic pathway set out in Scheme 6, described previously. One of skill in the art will recognize that many possible variations on this embodiment exist that will not result in deviation from the novel and unobvious aspects of the invention.

A. Bromination of anilines. An anhydrous dimethyl formamide (DMF) solution (40 mL) of a commercially available aniline (0.02 mol) was treated with N-bromosuccinimide (NBS, 1.1 eq.) at room temperature overnight. The resulting mixture was quenched by pouring it onto ice and extracted with ethyl acetate (EtOAc, 2 x 30 mL). The combined organic layers were washed with water (30 mL), brine (30 mL), dried over MgSO₄, filtered and concentrated to give the product.

B. Heck coupling. To an anhydrous triethylamine solution (TEA, 3 mL) of 2-bromo-R¹-substituted-aniline (0.006 mol) (1 eq), in 10 x 1.3 cm test tubes, was added *bis*-triphenylphosphine palladium chloride (2 mol%) at room temperature followed by the addition of copper iodide (2 mol%). To this heterogeneous mixture, the corresponding

terminal alkynol (1.5 eq.) and glass beads were added. The resulting mixture was allowed to react for 6h. at 80°C under vigorous vortex shaking. Upon cooling, the reaction mixture was filtered through a celite bed (in 5 mL disposable syringes). Concentration under high vacuum (speed-vac) afforded the product.

C. Cyclization to form indoles. To an anhydrous acetonitrile (3 mL) solution of alkyne-substituted aniline in 10 x 1.3 cm test tubes at room temperature was added palladium chloride (2mol%) followed by the addition of glass beads. The resulting mixture was heated to 60 °C for 1h under vigorous vortex shaking. Upon cooling, the reaction mixture was filtered through a bed of celite (in 5 mL disposable syringes). The solvent was evaporated under high vacuum (speed-vac) to afford the products.

D. Quaternization with amines. To a cooled (0 °C) solution of the indole alcohol in aromatic amine (pyridine, quinoline, or isoquinoline) (2 mL), under a nitrogen atmosphere in 10 x 1.3 cm test tubes, was added trifluoromethanesulfonyl anhydride (TF_3O) (1.3 eq.). The resulting solution was allowed to react for 6 h. The reaction mixture was quenched by the addition of an ice-cold 1.5N HCl solution (3 mL) followed by the addition of EtOAc (4 mL). The organic layer was washed with water (3 mL), brine (3 mL), dried over MgSO_4 , and filtered through a silica gel column (1 x 2 cm, in 5 mL syringes) in order to remove unreacted organic materials. The column was then flushed with a dichloromethane:methanol (19:1) solution (4 mL). This extract was concentrated to afford the products.

E. Formation of isolated mesylate. To an anhydrous DCM solution (2 mL) of the indole alcohol was added TEA (1.5 eq.) at room temperature in 10 x 1.3 cm test tubes. The resulting solution was cooled to 0 °C and treated with methanesulfonyl chloride (1.1 eq.) for 1 h. The reaction mixture was quenched by the addition of water (3 mL), followed by DCM (3 mL). The organic layer was washed with brine (3 mL), dried over MgSO_4 , filtered through a celite bed (in 5 mL disposable syringes) and concentrated under high vacuum (speed-vac) to give the indole mesylates.

WO 99/36422

123

PCT/US99/00810

F. **Formation of ester.** To an anhydrous DMF solution (2 mL) of the indole mesylate (1 eq.) in 10 x 1.3 cm test tubes was added the corresponding carboxylic acid (R_3 -COOH, 2 eq.) followed by K_2CO_3 (2 eq.) and glass beads at room temperature. The resulting suspension was heated to 55 °C for 16 h under vigorous vortex shaking. Upon cooling the reaction mixture was quenched by adding water (3 mL) followed by ethyl acetate (3 mL). The organic layer was washed with brine (4 mL), dried under $MgSO_4$, filtered through a cotton bed (in 5 mL disposable syringes) and concentrated under high vacuum (speed-vac) to give the final ester.

EXAMPLE 5: GENERAL PROCEDURE FOR CRYSTALLIZATION, DATA COLLECTION AND DETERMINATION OF STRUCTURAL RELATIONSHIP BETWEEN NAD SYNTHETASE INHIBITOR COMPOUNDS AND THE NAD SYNTHETASE ENZYME.

A. **Crystallization.** Protein was expressed and purified as described in the literature. (Nessi, C., Albertini, A., Speranza, M.L. & Galizzi, A. *The out B gene of Bacillus subtilis codes for NAD⁺ synthetase*. *J. Biological Chemistry* 270, 6181-6185). Crystals were grown by vapor diffusion at 28° C from 21 - 23% polyethylene glycol (PEG) 400, 100 mM acetate buffer, pH 5.2, 50 mM $MgCl_2$, 2.5 mM β -mercapto ethanol. Inhibitors were dissolved in minimal volume of PEG 400 and then mixed with crystallization medium to final concentration of 5 - 10 mM in 23% v/v PEG 400. 10 μ l of protein solution (16 mg/ml in crystallization buffer) were mixed with 10 μ L of inhibitor in crystallization medium incubated at 28 ° C. The crystals of NAD synthetase complexed with inhibitors obtained belonged to space group P21 as described previously in the literature. (Rizzi, M., Nessi, C., Matteve, A., Coda, A. & Galizzi, A. *Crystal structure of NH_3 -dependent NAD⁺ synthetase from Bacillus subtilis*. *EMBO Journal* 15, 5125-5134 (1996)).

B. **Data collection.** Diffraction data for the different complexes of NAD synthetase with inhibitors were collected at ambient temperature or at 120° K with use of R-axisII and R-axisIV image plates and a rotating anode X-ray source, using Xstream

Cryosystem device. Data were processed with DENZO and SCALEPACK as described. (Otwinowski, Z., & Minor, W. Processing of X-ray data collected in oscillation mode. in Carter C.W Jr. and Sweet M.M (eds.), **Methods of Enzymology**, v. 76, 307-326, Academic Press, New York (1996)). All subsequent calculations were performed with CCP4 program suite. (CCP4. The SERC (UK) Collaborative Computing Project No. 4, *A suite of Programs for Protein Crystallography*, SERC Daresbury Laboratory, Warrington, UK, 1979.)

C. **Refinement.** All complexes of NAD synthetase with inhibitors were isomorphous with the recently solved structure NAD synthetase complexed with AMP, PPi, ATP and Mg^{2+} (Rizzi, M., Nessi, C., Bolognesi, M., Coda, A. & Galizzi, A. *Crystallization of NAD⁺ synthetase from Bacillus subtilis*. **Proteins** 26, 236-238 (1996). The coordinates from this structure excluding ligands and water molecules were used as a starting model for the free enzyme at 2.0 Å resolution. Rigid-body refinement followed by simulated annealing were carried out with X-PLOR (Brunger, A.T., **X-PLOR Version 3.1. A system for X-ray Crystallography and NMR** (Yale Univ Press, New Haven, CT, 1992)) until convergence was reached using all reflections to 2.0 Å resolution. The model of the free enzyme was subsequently used for phasing and refinement of the complexes of NAD synthetase with inhibitors. The procedure for refinement with X-PLOR of a particular model included first simulated annealing cycle and positional refinement of the protein. Inhibitors were manually built into $(F_o - F_c)_\alpha$ difference Fourier maps using QUANTA (Molecular Simulations) (Jones, T., Zou, J., Cowan, S. & Kjeldgaard, M. *Improved method for building protein models in electron density maps and the location of the errors in these models*. **Acta Crystallogr. A** 47, 110-119 (1991)) and O and refinement continued. A bulk solvent correction were then applied and ordered water molecules added following standard criteria.

EXAMPLE 6: "ONE-AT-A-TIME" *IN-VITRO* SCREENING METHOD

The "one-at-a-time" *in vitro* bacterial NAD synthetase enzyme activity assay described below was used to test for relative activities of selected active molecules and

synthetic dimers. The method was used to test selected NAD synthetase inhibitor compounds of the library herein, as well as commercially available compounds predicted to have bacterial NAD synthetase enzyme activity inhibitor capabilities.

A solution (1014 L) of 60 mM HEPES pH 8.5 with 20 mM KCl was prepared containing the following species: 0.210 mM ATP, 0.152 mM NaAD, 4 mM MgCl₂, 10 mM NH₄Cl, 0.21 mg/mL ADH, and 1% ETOH. A stock solution of test inhibitors was then prepared by dissolving solid samples into 100% DMSO. 20 L of the test compound stock solution was then added to the mixture to give the final test compound concentrations listed. To start the enzyme assay, 16 L of a 65 g/mL NAD Synthetase solution were added, the mixture was mixed three times, and the absorbance at 340 nm was then monitored kinetically for 400 s using an Aviv 14DS UV-Vis spectrophotometer. The initial kinetics trace from 30 to approximately 250 seconds after enzyme addition was then fitted to a straight line using linear regression, and this rate was then compared to that of a control containing no inhibitor, using the following formula to calculate % Inhibition: $\{(V_o - V)/V_o\} * 100\%$, where V_o is the rate of the reaction with no test compound present and V is the rate of the reaction with test the test compound added. Each compound was tested in triplicate, and the resulting values for % inhibition were averaged to give the listed value. IC₅₀ values were obtained for select compounds by assaying six different concentrations of test compound, in triplicate, at concentrations between 0.0 and 2.0 mM, and plotting the resulting % inhibition values against the -LOG of the test compound dose to reveal the concentration at which 50% inhibition was observed.

EXAMPLE 7: COMPARISON OF BACTERIAL NAD SYNTHETASE ACTIVITY IN DIFFERENT BACTERIA TYPES

To determine initially if a compound found active in the assays, Compound 864, was also an effective inhibitor of a variety of different bacteria, a standard antibiotic assay was performed. The results are summarized in Table 206. In this assay 250 µg of Compound 864 (25 µg/ml in DMSO) was spotted on 6 or 7 mm paper disks. Each disk was placed on separate 30 ml solid-medium plates layered with bacteria. Blood agar

WO 99/36422

126

PCT/US99/00810

plates were used for *Streptococcus*, and minimal-glucose plates were used for the other microorganisms in Table 206. DMSO controls provided negative results.

TABLE 206: INHIBITION OF GRAM +/- BACTERIA BY COMPOUND 864

BACTERIUM	STRAIN	GRAM + OR -	ZONE OF INHIBITION (mM)
<i>Escherichia coli</i> K-12	MG1655 (CGSC#6300)	-	9.5
<i>Escherichia coli</i> K-12	W3110 (CGSC#4474)	-	9.5
<i>Salmonella typhimurium</i>	LT2 TT366	-	10
<i>Streptococcus pneumonia</i>	D39	+	12
<i>Streptococcus pneumoniae</i>	WU2	+	15
<i>Bacillus subtilis</i>	A700	+	19.5

Compound 864 demonstrates inhibitory activity from which bacterial NAD synthetase inhibitory activity in a variety of bacteria may be extrapolated. Further, it is evident from this data that inhibition of bacterial NAD synthetase enzyme corresponds to inhibition of both gram positive and gram negative bacteria. Such data also demonstrates the effectiveness of the compounds herein as bacteriacidal agents, antimicrobial agents and disinfectants.

EXAMPLE 8: ADAPTATION OF ENZYME ASSAY TO HIGH THROUGH-PUT SCREENING OF INHIBITORS

The enzyme kinetics assay for bacterial NAD synthetase enzyme inhibitory activity utilized as the primary biological screen, discussed previously as the "one-at-a-time" *in vitro* assay, was adapted to a microtiter plate format so that many compounds could be screened in a short time *i.e.*, in a high-throughput system.

The final reaction mixture included 0.2ml of 60mM HEPPS buffer, pH 8.5, 10mM

WO 99/36422

127

PCT/US99/00810

MgCl₂, 19mM NH₄Cl, 20mM KCL, 0.1mM NaAD, 0.3% n-Octyl--D-Glucopyranoside, 1% ethanol, 1g/ml NAD synthetase, 62.5g/ml yeast alcohol dehydrogenase, 0.2mM ATP and 2.5% DMSO.

The measurement of inhibitory activities of the test compounds was conducted using a high through-put screening system (HTS system). The HTS system utilizes an integrated Sagian 2M ORCA robotic system coordinating the functions of a Beckman Biomek 2000 liquid handler and a Molecular Devices SpectraMax Plus spectrophotometer. The 2M ORCA robotic station was responsible for the movement of all hardware and the integration of multiple stations on the worksurface. The Biomek 2000 is programmed to perform all phases of liquid dispensing and mixing. The SpectraMax Plus spectrophotometer was equipped to monitor absorbance in a 96- well plate format.

The present assay was designed for a 96-well plate format and begun with the dispensing of 0.170ml of reaction buffer containing 60mM HEPPS buffer, pH 8.5, 10mM MgCl₂, 19mM NH₄Cl, 20mM KCL, 0.118mM NaAD, 0.3% n-Octyl--D-Glucopyranoside, 1.18% ethanol, 1.18g/ml NAD synthetase, and 73.75g/ml yeast alcohol dehydrogenase. Once the Biomek 2000 has completed this stage of the liquid handling, a 0.005ml volume of test compound in 100% DMSO or a 0.005ml of DMSO was dispensed in the reaction well. The Biomek 2000 mixed these components utilizing a predefined mixing program. The reaction was initiated by the addition of 0.025ml of a solution of 1.6mM ATP dissolved in 60mM HEPPS buffer, pH 8.5, 10mM MgCl₂, 19mM NH₄Cl, 20mM KCL, 2.5% DMSO, and 0.3% n-Octyl--D-Glucopyranoside. The reactions were monitored by measuring the increase in absorbance at 304nm. The linear portion of the reaction was monitored for 180sec. The initial velocity was determined using Softmax Pro, the software supplied with the Molecular Devices SpectraMax Plus spectrophotometer.

The compounds were supplied as a stock with a concentration of 50mM dissolved in 100% DMSO. An initial screen was conducted on all compounds using a 2 or 3 concentration screen. The 2 panel screen used concentrations of 0.2mM and 0.1mM for

WO 99/36422

128

PCT/US99/00810

the compounds. The 3 panel screen used concentrations of 0.2mM, 0.1mM, and 0.05mM.

From the initial screen, lead compounds which indicated the greatest inhibitory capacity were then subjected to a wider screen of concentrations (0.1mM to 0.005mM) to determine the apparent IC-50 values for each compound.

Double reciprocal plots of initial velocities have yielded the kinetic parameters given in the following table for the 2 mL cuvette assay. Also included in the table are the Km values obtained in the 0.2 mL microtiter plate assay. In this latter assay, a Beckmann/Sagian automated robotic system was applied in for high through-put screening in one preferred embodiment of the method.

TABLE 208: KINETIC DATA FOR HIGH THROUGH-PUT SCREENING METHOD

2 mL Assay			0.2 mL Assay
Substrate	Km (mM)	Vmax (nM/sec)	Km (mM)
Mg ⁺²	2.6	120	2.9
NH ₃	2.88	137	--
ATP	0.12	436	0.152
NaAD	0.075	286	0.076

With the preferred high through-put system and the adapted enzymatic screening assay for bacterial NAD synthetase inhibitory enzyme activity described previously, large numbers of compounds can be screened in a short period.

EXAMPLE 9: NAD SYNTHETASE INHIBITORY ACTIVITY OF COMPOUNDS

Compounds of the libraries herein were screened using the high through-put enzyme kinetics assays described above in Example 8. Tables 210, 212, 214 and 216 below present NAD synthetase enzyme inhibition data for a number of compounds of the libraries herein tested at 0.25 mM, 0.2 mM, 0.1 mM and 0.05 mM doses, respectively.

WO 99/36422

129

PCT/US99/00810

TABLE 210
COMPOUND ACTIVITIES AT 0.25 mM

	Table 210 0.25mM	
COMPOUND NUMBER		% INHIBITION
868		13.5
870		63.1
871		81.9
873		98.0
874		97.0
877		98.3
880		96.7
885		98.0
888		99.0
891		99.9
892		97.7
893		13.8
895		95.7
897		50.9
898		51.8
900		84.9
901		32.8
903		95.5
907		20.6
910		88.5
912		27.6
913		7.6
915		95.7
917		88.9
918		98.6
919		90.2
922		87.4
927		93.1
928		85.8
930		96.7
931		15.8
933		99.2
934		98.5
937		88.8
938		98.8
939		97.8

WO 99/36422

130

PCT/US99/00810

Table 210 0.25mM	
COMPOUND NUMBER	% INHIBITION
940	88.7

TABLE 212
COMPOUND ACTIVITIES AT 0.2Mm

COMPOUND ACTIVITIES AT 0.2mM				
		Table 212		
		0.2 mM		
Compound d Number	% Inhibition		Compound Number	% Inhibition
6	5.67		334	41.67
9	28.02		335	3.28
13	80.80		339	42.87
14	78.85		341	3.54
23	27.12		342	11.92
164	5.47		343	10.82
165	90.97		344	4.58
166	87.68		348	44.42
173	73.86		351	65.08
213	90.67		354	2.96
222	52.98		355	2.08
227	91.19		356	1.95
236	9.59		357	67.58
238	38.21		358	23.19
246	92.19		359	35.55
254	73.91		360	3.46
262	88.76		363	75.01
267	26.97		364	29.20
268	11.23		365	16.45
284	13.92		367	9.72
285	32.45		369	35.33
287	16.01		370	41.34
289	9.28		371	43.85
291	71.94		373	14.13
292	44.36		377	30.12
293	87.66		379	6.27
296	16.79		380	10.09
299	49.13		382	42.85
300	11.79		383	2.76
301	6.12		384	4.10
302	21.48		385	61.62

WO 99/36422

131

PCT/US99/00810

		Table 212 0.2 mM		
Compound d Number	% Inhibition		Compound Number	% Inhibition
303	50.56		386	28.75
305	54.83		388	25.86
306	33.93		389	12.44
307	4.40		392	10.89
308	33.71		394	4.62
310	38.29		399	15.22
311	29.67		401	14.26
318	14.94		403	5.07
322	14.40		405	6.07
323	28.08		406	10.96
324	34.99		407	24.14
329	30.77		408	7.04
330	23.96		409	19.02
410	8.77		474	2.45
411	8.84		476	17.49
413	4.76		477	10.15
414	6.91		478	9.76
415	7.72		482	17.07
417	14.59		483	7.31
418	5.95		484	39.95
419	24.28		486	4.97
420	9.16		488	17.65
421	1.86		489	5.87
422	16.23		490	2.96
423	12.09		491	8.24
425	19.12		492	2.59
428	26.53		493	9.12
429	13.01		494	17.44
430	1.20		495	6.80
431	10.77		496	36.97
432	13.21		497	29.10
434	5.36		498	47.31
435	17.24		499	25.59
436	11.57		501	4.98
437	6.91		502	44.08
438	9.45		503	37.04
440	12.69		505	25.51
441	11.80		506	21.74
443	5.51		507	26.18
445	5.43		508	51.84
446	13.78		509	78.00

WO 99/36422

132

PCT/US99/00810

		Table 212 0.2 mM		
Compound d Number	% Inhibition		Compound Number	% Inhibition
447	2.30		510	20.99
448	2.92		511	11.02
449	8.67		512	17.50
450	7.90		513	23.66
452	20.04		514	22.32
454	7.95		515	30.39
455	2.69		516	29.95
457	3.31		517	34.72
458	15.72		519	16.27
460	4.17		520	55.83
461	17.92		521	29.59
462	3.84		522	35.74
464	13.50		523	18.12
465	7.92		524	30.81
466	5.79		525	8.39
467	15.08		526	42.77
473	15.06		527	73.78
528	65.81		583	31.37
529	15.50		584	68.79
530	20.52		585	17.43
531	36.55		586	2.01
532	53.80		587	56.47
533	24.68		588	2.49
534	26.99		590	28.82
535	12.61		591	18.59
536	32.49		592	18.70
537	10.69		593	60.19
538	40.95		594	2.77
539	16.80		595	17.94
540	20.20		596	56.49
542	15.89		597	19.76
543	28.06		598	43.33
544	19.66		599	19.31
545	32.18		600	3.10
549	14.08		601	2.22
550	28.18		602	59.10
551	50.05		603	51.72
555	30.89		604	34.10
557	10.46		605	68.65
558	1.27		608	6.75
559	33.24		611	15.13

WO 99/36422

133

PCT/US99/00810

		Table 212 0.2 mM		
Compound d Number	% Inhibition		Compound Number	% Inhibition
560	46.91		614	8.32
561	24.70		617	2.02
562	46.44		619	19.53
563	22.68		620	19.03
564	26.95		627	11.19
565	15.63		630	10.72
566	29.72		636	17.36
567	22.51		640	1.45
568	18.95		645	4.31
569	34.84		648	5.82
571	17.47		653	20.59
572	31.02		654	2.11
573	26.24		659	25.47
574	11.95		662	8.39
575	42.01		663	15.43
576	2.05		672	2.63
577	20.58		673	1.81
578	30.96		682	6.65
579	12.57		685	7.81
581	21.66		697	4.28
582	6.13		700	2.54
712	12.59		864	19.33
740	7.23		865	46.43
741	30.47		867	70.33
742	28.20		967	19.51
744	95.85		968	88.52
745	85.38		969	83.16
760	2.28		970	96.65
761	6.88		979	38.72
762	40.05		980	74.86
763	66.50		981	95.16
764	79.25		982	93.74
862	9.05		990	92.16

WO 99/36422

134

PCT/US99/00810

TABLE 214
COMPOUND ACTIVITIES AT 0.1 mM

		Table 214 0.1 mM		
Compound Number	% Inhibition		Compound Number	% Inhibition
989	54.83		670	4.65
988	84.32		638	2.31
978	80.31		637	4.42
977	87.61		589	24.98
976	70.96		556	18.19
975	55.17		554	68.22
974	88.21		553	49.49
973	97.77		552	15.24
972	96.76		548	24.59
971	100.00		547	8.32
965	8.48		546	4.72
943	21.38		541	10.26
942	97.79		518	30.39
941	100.00		500	18.25
936	97.75		487	9.88
924	97.67		472	12.76
921	96.65		451	2.94
909	97.17		444	8.55
904	47.68		439	2.57
894	91.13		433	1.79
889	93.60		426	5.49
886	94.50		402	4.71
882	94.50		397	4.51
881	90.89		396	3.64
879	99.58		395	20.85
878	96.43		387	29.97
876	95.41		381	25.05
875	93.56		376	37.32
872	98.31		375	60.14
853	73.46		374	31.84
850	87.46		373	7.72
849	90.92		368	21.10
848	70.02		362	8.31
832	78.64		361	16.08
831	26.21		355	3.31
769	98.31		352	32.69

WO 99/36422

135

PCT/US99/00810

		Table 214 0.1 mM		
Compound Number	% Inhibition		Compound Number	% Inhibition
768	98.64		349	86.56
767	95.96		346	42.57
766	91.22		345	37.00
765	89.99		344	54.05
749	98.19		344	10.78
748	98.38		338	27.28
747	97.81		337	35.94
746	91.27		336	18.02
743	94.10		333	26.29
715	20.73		332	12.27
676	1.46		328	47.85
327	55.31		297	50.83
326	16.11		295	25.05
325	53.22		290	12.89
321	37.25		288	42.38
320	44.72		269	51.12
319	16.99		245	7.01
317	25.04		230	93.06
316	41.58		229	99.35
315	77.23		228	95.08
314	9.19		214	82.84
313	27.37		182	95.41
312	10.25		154	9.24
309	41.47		82	9.68
304	29.48		12	62.22

WO 99/36422

136

PCT/US99/00810

TABLE 216
COMPOUND ACTIVITIES AT 0.05 mM

Table 216 0.05mM		
Compound Number		% Inhibition
944		2.06
948		2.52
950		7.32
960		6.37
964		1.18
966		8.25
983		92.49
984		87.50
985		92.14
986		30.80

Table 218 sets forth the various potent compounds ("lead compounds") of the NAD synthetase enzyme inhibitor compound libraries disclosed herein. The potency of the compounds is expressed according to IC_{50} values. The IC_{50} value is that amount of NAD synthetase enzyme inhibitor compound required to inhibit the enzyme by 50%.

WO 99/36422

137

PCT/US99/00810

TABLE 218
IC 50 DATA
LEAD COMPOUNDS

		Table 218		
Compound Number	IC 50(μ M)		Compound Number	IC 50(μ M)
13	50		879	40
174	40		882	90
182	60		884	45
190	50		886	80
213	65		887	25
214	30		889	75
228	60		891	80
229	25		894	50
230	12.5		906	25
270	60		909	25
315	100		917	60
349	75		921	25
745	85		924	25
746	50		936	60
747	70		939	25
748	30		941	50
749	25		942	75
765	90		970	55
766	65		972	40
767	60		973	45
768	30		974	35
769	20		975	38
832	90		976	20
848	90		977	10
849	70		981	60
850	80		982	60
853	45		983	25
869	40		984	20
872	50		985	15
875	45		986	10
876	75		988	10
878	80		990	20

WO 99/36422

138

PCT/US99/00810

Table 220 sets out screening results for a selection of compounds from the libraries of bacterial NAD synthetase enzyme inhibitor compounds of the invention herein. As apparent from the table, all compounds tested exhibit some inhibitory activity against *Staphylococcus epidermitis* and, accordingly, the compounds exhibit effectiveness as antimicrobial agents, antibacterial agents and disinfecting agents.

**TABLE 220: SCREENING RESULTS OF NAD SYNTHETASE INHIBITOR
COMPOUNDS AGAINST *S. EPIDERMITIS***

(Sorted by Percent Inhibition)

Table 220 <i>S. EPIDERMITIS</i>		
Compound Number	Concentration Screened	% Inhibition
237	10uM	100.00
593	100uM	100.00
587	100uM	100.00
518	100uM	100.00
375	100uM	100.00
374	100uM	100.00
369	100uM	100.00
363	100uM	100.00
362	100uM	100.00
357	100uM	100.00
339	100uM	100.00
333	100uM	100.00
327	100uM	100.00
321	100uM	100.00
315	100uM	100.00
303	100uM	100.00
297	100uM	100.00
291	100uM	100.00
345	100uM	99.86
809	10uM	99.81
512	100uM	99.71
288	10uM	99.65
524	100uM	99.57
351	100uM	99.57
254	10uM	99.39
238	10uM	99.39

Table 220 <i>S. EPIDERMITIS</i>		
Compound Number	Concentration Screened	% Inhibition
839	10uM	99.35
12	10uM	99.22
500	100uM	99.14
309	100uM	99.07
835	10uM	99.03
851	10uM	98.90
841	10uM	98.90
840	10uM	98.77
749	100uM	98.73
174	10uM	98.71
506	100uM	98.64
829	10uM	98.64
853	10uM	98.58
852	10uM	98.58
14	10uM	98.58
285	100uM	98.57
13	10uM	98.54
222	10uM	98.50
560	100uM	98.43
381	100uM	98.43
748	100uM	98.38
173	10uM	98.30
566	100uM	98.21
214	100uM	98.13
834	10uM	98.13
808	10uM	98.06
833	10uM	98.00
229	100uM	97.95
747	10uM	97.93
602	100uM	97.93
13	10uM	97.80
578	100uM	97.79
744	10uM	97.74
190	100uM	97.71
182	100uM	97.69
824	10uM	97.67
743	10uM	97.67
387	100uM	97.64
380	100uM	97.64
270	10uM	97.48
764	10uM	97.48

Table 220 <i>S. EPIDERMITIS</i>		
Compound Number	Concentration Screened	% Inhibition
554	100uM	97.43
213	10uM	97.41
828	10uM	97.29
804	10uM	97.29
807	10uM	97.22
823	10uM	97.03
542	100uM	96.93
746	10uM	96.83
228	100uM	96.78
13	10uM	96.77
536	100uM	96.64
572	100uM	96.57
227	10uM	96.46
548	100uM	96.43
596	100uM	96.36
386	100uM	96.36
14	10uM	96.19
768	100uM	96.11
584	100uM	96.07
769	100uM	95.94
827	10uM	95.86
12	10uM	95.73
262	10uM	95.50
230	100uM	95.48
745	10uM	95.09
821	10uM	95.02
553	10uM	94.92
832	10uM	94.70
295	10uM	94.48
590	100uM	94.43
865	100uM	94.40
826	10uM	92.57
261	10uM	92.51
767	100uM	91.76
368	100uM	91.36
766	10uM	90.50
246	10uM	90.26
296	10uM	87.47
864	100uM	87.03
831	10uM	84.68
281	10uM	84.23

WO 99/36422

141

PCT/US99/00810

Table 220 <i>S. EPIDERMITIS</i>		
Compound Number	Concentration Screened	% Inhibition
825	10uM	83.13
165	10uM	76.36
372	10uM	67.34
820	10uM	65.74
556	10uM	60.18
267	10uM	56.54
850	10uM	56.50
805	10uM	50.87
865	10uM	50.42
552	10uM	50.00
861	10uM	49.58
855	10uM	49.58
865	10uM	48.55
862	10uM	48.29
822	10uM	46.41
191	10uM	46.32
269	10uM	46.12
605	100uM	44.29
663	100uM	44.28
599	100uM	44.14
405	10uM	44.01
538	10uM	43.05
830	10uM	42.99
727	10uM	42.23
180	10uM	40.33
661	10uM	39.31
657	100uM	37.12
464	10uM	35.45
623	100uM	34.17
640	10uM	33.86
610	10uM	33.51
682	10uM	32.56
9	10uM	31.80
453	10uM	31.13
439	10uM	30.57
589	10uM	29.35
530	100uM	27.36
654	10uM	25.20
243	10uM	23.43
458	10uM	22.77
680	10uM	22.48

Table 220 <i>S. EPIDERMITIS</i>		
Compound Number	Concentration Screened	% Inhibition
632	100uM	22.42
486	10uM	22.28
431	10uM	22.28
686	10uM	22.14
166	10uM	21.66
235	10uM	20.50
659	100uM	20.41
614	100uM	20.35
627	100uM	20.10
847	10uM	19.84
617	100uM	19.54
356	100uM	19.29
624	100uM	19.16
704	10uM	19.07
513	100uM	17.86
838	10uM	17.65
423	10uM	16.85
726	10uM	16.76
426	10uM	16.57
573	10uM	16.09
459	10uM	16.09
215	10uM	15.87
507	100uM	15.86
411	10uM	15.74
643	10uM	15.46
545	10uM	15.39
171	10uM	15.33
342	10uM	14.97
648	100uM	14.57
687	10uM	14.44
693	10uM	14.37
626	100uM	14.26
471	10uM	14.07
630	100uM	13.69
203	10uM	13.62
651	100uM	13.51
647	100uM	13.38
728	10uM	13.28
709	10uM	12.94
665	100uM	12.75
620	100uM	12.69

Table 220 <i>S. EPIDERMITIS</i>		
Compound Number	Concentration Screened	% Inhibition
631	10uM	12.19
677	100uM	12.12
437	10uM	11.84
615	100uM	11.81
621	100uM	11.75
655	10uM	11.51
675	100uM	11.37
519	10uM	11.35
669	100uM	11.24
445	10uM	11.21
491	10uM	11.14
476	10uM	11.14
618	100uM	11.06
492	10uM	11.00
684	10uM	10.83
638	100uM	10.55
612	100uM	10.24
529	10uM	10.15
634	10uM	10.08
690	10uM	10.01
608	100uM	9.86
422	10uM	9.82
611	100uM	9.67
392	10uM	9.61
562	10uM	9.44
765	10uM	9.31
683	10uM	9.26
199	10uM	9.26
645	100uM	9.23
200	10uM	9.20
606	100uM	9.17
432	10uM	8.91
642	100uM	8.86
598	10uM	8.86
531	10uM	8.77
440	10uM	8.77
65	10uM	8.66
653	100uM	8.42
729	10uM	8.24
452	10uM	8.22
641	100uM	8.10

Table 220 <i>S. EPIDERMITIS</i>		
Compound Number	Concentration Screened	% Inhibition
465	10uM	8.08
344	10uM	8.08
622	10uM	7.97
501	100uM	7.93
503	10uM	7.82
417	10uM	7.80
625	10uM	7.77
24	10uM	7.76
449	10uM	7.73
412	10uM	7.73
650	100uM	7.73
674	10uM	7.70
443	10uM	7.66
350	10uM	7.59
635	100uM	7.47
450	10uM	7.45
639	100uM	7.41
609	100uM	7.35
236	10uM	7.29
394	10uM	7.03
710	10uM	6.95
636	100uM	6.72
706	10uM	6.68
629	100uM	6.66
455	10uM	6.55
406	10uM	6.41
225	10uM	6.40
326	10uM	6.27
300	10uM	6.20
188	10uM	6.06
543	10uM	5.99
390	10uM	5.92
444	10uM	5.85
428	10uM	5.85
397	10uM	5.85
355	10uM	5.78
671	100uM	5.72
434	10uM	5.64
367	10uM	5.64
670	10uM	5.59
616	10uM	5.59

WO 99/36422

145

PCT/US99/00810

Table 220 <i>S. EPIDERMITIS</i>		
Compound Number	Concentration Screened	% Inhibition
579	10uM	5.57
451	10uM	5.57
361	10uM	5.57
633	100uM	5.53
676	10uM	5.52
400	10uM	5.50
537	10uM	5.43
438	10uM	5.29
391	10uM	5.29
367	10uM	5.22
740	10uM	5.17
403	10uM	4.87
780	10uM	4.78
863	10uM	4.72
539	10uM	4.67
457	10uM	4.67
312	10uM	4.60
550	10uM	4.40
482	10uM	4.39
306	10uM	4.32
703	10uM	4.29
681	10uM	4.22
644	100uM	4.02
701	10uM	3.88
664	10uM	3.88
477	10uM	3.69
456	10uM	3.69
446	10uM	3.69
707	10uM	3.61
700	10uM	3.61
220	10uM	3.61
181	10uM	3.47
662	10uM	3.27
549	10uM	3.13
462	10uM	3.13
568	10uM	3.10
668	10uM	3.07
429	10uM	3.06
318	10uM	2.99
488	10uM	2.72
694	10uM	2.59

Table 220 <i>S. EPIDERMITIS</i>		
Compound Number	Concentration Screened	% Inhibition
656	10uM	2.59
652	10uM	2.52
284	10uM	2.51
167	10uM	2.45
409	10uM	2.44
208	10uM	2.32
843	10uM	2.20
364	10uM	2.16
742	10uM	2.13
585	10uM	2.09
416	10uM	2.09
415	10uM	1.95
223	10uM	1.91
408	10uM	1.88
338	10uM	1.67
603	10uM	1.60
540	10uM	1.60
672	10uM	1.57
219	10uM	1.57
396	10uM	1.53
373	10uM	1.53
673	10uM	1.50
658	10uM	1.43
613	10uM	1.36
483	10uM	1.25
424	10uM	1.11
646	10uM	1.09
698	10uM	1.02
359	100uM	1.01

Table 222 sets out the MIC₈₅ (minimum inhibitory concentration to achieve 85% inhibition) values against *B. subtilis* (gram positive bacteria) for a number of lead compounds within a library of bacterial NAD synthetase enzyme inhibitor compounds from Table 201 above and of the invention herein. This table demonstrates that the compounds of the invention herein are useful as antibacterial agents, antimicrobial agents and disinfecting agents.

TABLE 222: MIC₈₅ RESULTS OF NAD SYNTHETASE
ENZYME INHIBITOR LEAD COMPOUNDS AGAINST *B. SUBTILIS*
(Sorted by MIC₈₅)

COMPOUND NUMBER	TABLE 222 <i>B. SUBTILIS</i>	MIC ₈₅ (μM)
769		3
749		3
977		10
986		10
988		10
990		10
230		10
976		10
985		10
984		30

Table 224 sets out the MIC₈₅ (minimum inhibitory concentration to achieve 85% inhibition) against *Staphylococcus epidermitis* for a number of compounds within a library of bacterial NAD synthetase enzyme inhibitor compounds of the invention herein. This table demonstrates that the compounds of the invention herein are useful as antibacterial agents, antimicrobial agents and disinfecting agents.

WO 99/36422

148

PCT/US99/00810

TABLE 224: MIC₃₅ RESULTS OF NAD SYNTHETASE ENZYME
INHIBITOR COMPOUNDS AGAINST *S. EPIDERMITS*

(Sorted by MIC₃₅ Values)

Table 224	
<i>S.</i> <i>EPIDERMITS</i>	
Compound Number	MIC ₃₅ (μM)
190	3
229	3
230	3
238	3.3
824	3.7
826	3.7
827	3.7
828	3.7
834	3.7
835	3.7
14	10
173	10
174	10
182	10
213	10
214	10
228	10
237	10
254	10
262	10
270	10
295	10
553	10
554	10
743	10
746	10
747	10
748	10
749	10
767	10

WO 99/36422

149

PCT/US99/00810

Compound Number	Table 224 S. EPIDERMITS	MIC ₃₅ (μM)
768		10
769		10
807		10
809		10
823		10
833		10
840		10
841		10
12		30
13		30
222		30
227		30
246		30
261		30
288		30
291		30
296		30
297		30
315		30
362		30
363		30
372		30
374		30
375		30
500		30
512		30
518		30
552		30
744		30
745		30
764		30
766		30
804		30
808		30
821		30
831		30
832		30
839		30
851		30
852		30

	Table 224	
	S.	
	EPIDERMITS	
Compound Number		MIC ₃₅ (μM)
853		30

EXAMPLE 10: *IN VITRO* TOXICITY IN HUMAN CELLS OF SELECTED COMPOUNDS WITHIN THE LIBRARY OF COMPOUNDS

Using the K562 human myeloid cell line, stock solutions of inhibitors in DMSO were added to the cell culture in RPMI 1640 medium which contained 10% fetal calf serum and was kept under a 10% CO₂ atmosphere. The final concentration of DMSO was less than 5%, and a DMSO control was included. The mixtures were incubated at doubling dilutions (approximately 1000 μM – 10 μM range) of inhibitor for 15 hours at 37°C. At this time propidium iodide was added (1 μg/mL) and the mixture incubated at 30 min. at 4°C. The cells were washed once with medium, centrifuged, and resuspended in 2% bovine serum albumin/phosphate-buffered saline. The cell suspension was then run through a FACSaliber flow cytometer and approximately 5000 cells were counted. The proportion of dead (stained) cells was determined, and the percent of live cells was expressed as % controls. The minimum toxic concentration was the lowest tested concentration of inhibitor which caused a significantly lower percentage of live cells as compared to controls.

TABLE 226: HUMAN CELL TOXICITY OF
SELECTED LEAD COMPOUNDS

	Table 226	
	Human Cell Toxicity	
Compound Number		Minimum Toxic Dose (μM)
940		1000
949		200
951		500
409		200
948		200
270		200
939		500
947		200

WO 99/36422

151

PCT/US99/00810

953		100
274		300











It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention.







Throughout this application, where publications are referenced, the disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.






Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with the true scope and spirit of the invention being indicated by the following claims.


WHAT IS CLAIMED IS:

1. A bacterial NAD synthetase enzyme inhibitor compound of the structure:












832




848



849



850








853

WO 99/36422


156

PCT/US99/00810







384




386




887




889




891



894



906











909

WO 99/36422


158

PCT/US99/00810







970




972




973




974



975



976











977


WO 99/36422

160

PCT/US99/00810




2. A bacterial NAD synthetase enzyme inhibitor compound, having Structure 2:



Structure 2

wherein n is an integer of from 1 to 12, R₁ - R₇ each, independently, is an H, an unsubstituted or a substituted cyclic or aliphatic group, or a branched or an unbranched group, and wherein the linker is a cyclic or aliphatic, branched or an unbranched alkyl, alkenyl, or an alkynyl group and wherein the linker may also contain heteroatoms.


3. The compound of Claim 2 wherein n is an integer of from 3 to 10.
4. The compound of Claim 2 wherein n is an integer of from 5 to 9.
5. The compound of Claim 2 wherein n is an integer of from 6 to 9.
6. The compound of Claim 2 wherein R₁ - R₇ each, independently, is an H, alkyl, alkenyl, alkynyl, or an aryl group.
7. The compound of Claim 2 wherein R₁-R₇, each, independently, is a hydroxyl, ketone, nitro, amino, amidino, guanidino, carboxylate, amide, sulfonate, or halogen or the common derivatives of these groups.
8. A bacterial NAD synthetase enzyme inhibitor compound, having Structure 4:



Structure 4

wherein X is a C, N, O or S within a monocyclic or bicyclic moiety, A and B represent the respective sites of attachment for the linker, n is an integer of from 1 to 12, R₁-R₇ each, independently, is an H, an unsubstituted or a substituted cyclic group, or an aliphatic group, or a branched or an unbranched group, and the linker is a saturated or unsaturated cyclic group or an aliphatic branched or unbranched alkyl, alkenyl or alkynyl group, and wherein the linker may also contain heteroatoms.

9. The compound of Claim 8 wherein n is an integer of from 3 to 10.
10. The compound of Claim 8 wherein n is an integer of from 5 to 9.
11. The compound of Claim 8 wherein n is an integer of from 6 to 9.
12. The compound of Claim 8 wherein R₁-R₇, each, independently, is an H, alkyl, alkenyl, alkynyl, or an aryl group.
13. The compound of Claim 8 wherein R₁-R₇, each, independently, is a hydroxyl, ketone, nitro, amino, amidino, guanidino, carboxylate, amide, sulfonate, or halogen or the common derivatives of these groups.
14. A bacterial NAD synthetase enzyme inhibitor compound of Structure 6:



Structure 6


wherein X is C, N, O or S, Y is C, N, O, S, carboxy, ester, amide, or ketone, A and B represent the respective sites of attachment for a linker, n is an integer of from 1 to 12, and R₁-R₇, each, independently, is an H, unsubstituted or substituted cyclic group or an aliphatic group, a branched or an unbranched group, and the linker is a saturated or unsaturated cyclic or aliphatic group, branched or unbranched alkyl, alkenyl, or alkynyl group and wherein the linker may also contain heteroatoms.

15. The compound of Claim 14 wherein n is an integer of from 3 to 10.
16. The compound of Claim 14 wherein n is an integer of from 5 to 9.
17. The compound of Claim 14 wherein n is an integer of from 6 to 9.
18. The compound of Claim 14 wherein R₁-R₇, each, independently, is an H, alkyl, alkenyl, or alkynyl, or an aryl group.
19. The compound of Claim 14 wherein R₁-R₇, each, independently, is an H, hydroxyl, ketone, nitro, amino, amidino, guanidino, carboxylate, amide, sulfonate, or halogen and the common derivatives of these groups.
20. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 8:

WO 99/36422

164


PCT/US99/00810



Structure 8

wherein n is an integer of from 1 to 12, R_1 is an H, methoxy, benzyloxy, or nitro and R_2 is 3-pyridyl, N-methyl-3-pyridyl, 3-quinoliny, N-methyl-3-quinoliny, 3-(dimethylamino)phenyl, 3-(trimethylammonio)phenyl, 4-(dimethylamino)phenyl, 4-(trimethylammonio)phenyl, 4-(dimethylamino)phenylmethyl, or 4-(trimethylammonio)phenylmethyl.

21. The compound of Claim 20 wherein n is an integer of from 3 to 10.
22. The compound of Claim 20 wherein n is an integer of from 5 to 9.
23. The compound of Claim 20 wherein n is an integer of from 6 to 9.
24. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 10:



Structure 10

wherein n is an integer of from 1 to 12, R_1 is an H, CO_2H , $-\text{OCH}_3$, or $-\text{OCH}_2\text{Ph}$, R_2 is H, CO_2H , or $\text{CH}=\text{CHCO}_2\text{H}$, R_3 is H or CO_2H , and Y is N-linked pyridine-3-carboxylic acid, N-linked pyridine, N-linked quinoline, or N-linked isoquinoline.


25. The compound of Claim 24 wherein n is an integer of from 3 to 10.
26. The compound of Claim 24 wherein n is an integer of from 5 to 9.

WO 99/36422

165

PCT/US99/00810


27. The compound of Claim 24 wherein n is an integer of from 6 to 9.
28. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 12:



Structure 12

wherein n is an integer of from 1 to 12, R₁ is H, F, or NO₂, R₂ is H, CH₃, CF₃, NO₂, phenyl, n-butyl, isopropyl, F, phenyloxy, triphenylmethyl, methoxycarbonyl, methoxy, carboxy, acetyl, or benzoyl, R₃ is H or CF₃, and Y is N-linked pyridine-3-carboxylic acid, N-linked pyridine, N-linked quinoline, or N-linked isoquinoline.

29. The compound of Claim 28 wherein n is an integer of from 3 to 10.
30. The compound of Claim 28 wherein n is an integer of from 5 to 9.
31. The compound of Claim 28 wherein n is an integer of from 6 to 9.
32. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 14:



Structure 14

wherein n is an integer of from 1 to 12, R₁ is H, phenyloxy, isopropyl, acetyl, or benzoyl, R₂ is H or CF₃, and Y is 3-(dimethylamino)phenyl, 3-(trimethylammonio)phenyl, 4-(dimethylamino)phenyl, 4-


WO 99/36422

166

PCT/US99/00810

(trimethylammonio)phenyl, 2-(phenyl)phenyl, diphenylmethyl, 3-pyridyl, 4-pyridyl, or pyridine-3-methyl.

33. The compound of Claim 32 wherein n is an integer of from 3 to 10.
34. The compound of Claim 32 wherein n is an integer of from 5 to 9.
35. The compound of Claim 32 wherein n is an integer of from 6 to 9.
36. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 16:



STRUCTURE 16


wherein R is H or CO₂CH₃, and n is an integer of from 1 to 4.

37. The compound of Claim 36 wherein n is an integer of from 2 to 3.
38. The compound of Claim 36 wherein n is 3.
39. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 18:

WO 99/36422

167


PCT/US99/00810



Structure 18


wherein R is H or CO_2CH_3 and n is an integer of from 1 to 4.

40. The compound of Claim 39 wherein n is an integer of from 2 to 3.
41. The compound of Claim 39 wherein n is 3.
42. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 100:




Structure 100

wherein R' is:



and n is an integer of from 1 to 12.

43. The compound of Claim 42 wherein n is an integer of from 3 to 10.
44. The compound of Claim 42 wherein n is an integer of from 5 to 9.
45. The compound of Claim 42 wherein n is an integer of from 6 to 9.
46. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 101:






Structure 101

WO 99/36422


169

PCT/US99/00810

wherein R' is:




wherein R1 is:



wherein the R group in Fragments A-G is a benzyl group, a methyl group or a hydrogen and wherein n is an integer of from 1 to 12.

47. The compound of Claim 46 wherein n is an integer of from 3 to 10.
48. The compound of Claim 46 wherein n is an integer of from 5 to 9.
49. The compound of Claim 46 wherein n is an integer of from 6 to 9.
50. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 130:



Structure 130


WO 99/36422

171

PCT/US99/00810

wherein n is an integer of from 1 to 12.


51. The compound of Claim 50 wherein n is an integer of from 3 to 10.
52. The compound of Claim 50 wherein n is an integer of from 5 to 9.
53. The compound of Claim 50 wherein n is an integer of from 6 to 9.
54. A compound of Structure 132:



Structure 132

wherein n is an integer of from 1 to 12 and R is 5-H, 6-CF₃, 5-CH₃, 5,7-diF, 5,7-diNO₂, 5-Butyl, 5-iPropyl, 5-Phenyl, 5-NO₂, 5-Trityl, 5-F, 5-OPh, 5-COPh, 5-CF₃, 5-COCH₃, 5-OCH₃, 5-COOCH₃ or 5-COOH.

55. The compound of Claim 54 wherein n is an integer of from 3 to 10.
56. The compound of Claim 54 wherein n is an integer of from 5 to 9.
57. The compound of Claim 54 wherein n is an integer of from 6 to 9.
58. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 134:



Structure 134

wherein n is an integer of from 1 to 12 and R is 5-H, 6-CF₃, 5-CH₃, 5,7-diF, 5,7-diNO₂, 5-Butyl, 5-iPropyl, 5-Phenyl, 5-NO₂, 5-Trityl, 5-F, 5-OPh, 5-COPh, 5-CF₃,


WO 99/36422

172

PCT/US99/00810

5-COCH₃, 5-OCH₃, 5-COOCH₃, or 5-COOH.


59. The compound of Claim 58 wherein n is an integer of from 3 to 10.
60. The compound of Claim 58 wherein n is an integer of from 5 to 9.
61. The compound of Claim 58 wherein n is an integer of from 6 to 9.
62. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 136:



Structure 136

wherein n is an integer of from 1 to 12 and R is 5-H, 6-CF₃, 5-CH₃, 5,7-diF, 5,7-diNO₂, 5-Butyl, 5-iPropyl, 5-Phenyl, 5-NO₂, 5-Trityl, 5-F, 5-OPh, 5-COPh, 5-CF₃, 5-COCH₃, 5-OCH₃, 5-COOCH₃, or 5-COOH.

63. The compound of Claim 62 wherein n is an integer of from 3 to 10.
64. The compound of Claim 62 wherein n is an integer of from 5 to 9.
65. The compound of Claim 62 wherein n is an integer of from 6 to 9.
66. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 138:



Structure 138


wherein n is an integer of from 1 to 12 and R is 5-CF₃, 5-OPh, 5-iPropyl, 5-COCH₃, or 5-COPh and Y is 3-N,N-dimethylamino(phenyl), 4-N,N-dimethylamino(phenyl), or 2-Ph.

WO 99/36422

173

PCT/US99/00810


67. The compound of Claim 66 wherein n is an integer of from 3 to 10.
68. The compound of Claim 66 wherein n is an integer of from 5 to 9.
69. The compound of Claim 66 wherein n is an integer of from 6 to 9.
70. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 140:



Structure 140

wherein n is an integer of from 1 to 12, R is 5-CF₃, 5-OPh, 5-iPropyl, 5-COCH₃, or 5-COPh, and Z is CH(Ph)₂ or 3-Pyridyl.

71. The compound of Claim 70 wherein n is an integer of from 3 to 10.
72. The compound of Claim 70 wherein n is an integer of from 5 to 9.
73. The compound of Claim 70 wherein n is an integer of from 6 to 9.
74. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 142:



Structure 142

wherein n is an integer of from 1 to 12 and R is 6-CF₃, 5-OPh, 5-iPropyl, 5-COCH₃, or 5-COPh.


75. The compound of Claim 74 wherein n is an integer of from 3 to 10.
76. The compound of Claim 74 wherein n is an integer of from 5 to 9.

WO 99/36422

174

PCT/US99/00810


77. The compound of Claim 74 wherein n is an integer of from 6 to 9.
78. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 144:



Structure 144

wherein n is an integer of from 1 to 12 and R is 6- CF_3 , 5-OPh, 5-iPropyl, 5- $COCH_3$, or 5-COPh.

79. The compound of Claim 78 wherein n is an integer of from 3 to 10.
80. The compound of Claim 78 wherein n is an integer of from 5 to 9.
81. The compound of Claim 78 wherein n is an integer of from 6 to 9.
82. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 146:



Structure 146

wherein n is an integer of from 1 to 12.


83. The compound of Claim 82 wherein n is an integer of from 3 to 10.
84. The compound of Claim 82 wherein n is an integer of from 5 to 9.
85. The compound of Claim 82 wherein n is an integer of from 6 to 9.

WO 99/36422

175


PCT/US99/00810

86. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 148:



Structure 148.

87. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 150:



Structure 150


wherein R is an integer of from 1 to 12.

88. The compound of Claim 87 wherein n is an integer of from 3 to 10.
 89. The compound of Claim 87 wherein n is an integer of from 5 to 9.
 90. The compound of Claim 87 wherein n is an integer of from 6 to 9.
 91. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 152:

WO 99/36422

176


PCT/US99/00810



Structure 152

wherein n is an integer of from 1 to 12.

92. The compound of Claim 91 wherein n is an integer of from 3 to 10.
93. The compound of Claim 91 wherein n is an integer of from 5 to 9.
94. The compound of Claim 91 wherein n is an integer of from 6 to 9.
95. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 154:



Structure 154


wherein Z is CH(diPh), 4-(N,N-dimethylamino)phenyl, CH₂CH₂-(3-pyridyl), or (2-phenyl)-phenyl.

96. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 156:

WO 99/36422

177


PCT/US99/00810



Structure 156

wherein n is an integer of from 1 to 12 and R is -OCH₃ or -OCH₂Ph.

97. The compound of Claim 96 wherein n is an integer of from 3 to 10.
98. The compound of Claim 96 wherein n is an integer of from 5 to 9.
99. The compound of Claim 96 wherein n is an integer of from 6 to 9.
100. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 158:



Structure 158

wherein n is an integer of from 1 to 12 and R is -OCH₃ or -OCH₂Ph.


101. The compound of Claim 100 wherein n is an integer of from 3 to 10.
102. The compound of Claim 100 wherein n is an integer of from 5 to 9.
103. The compound of Claim 100 wherein n is an integer of from 6 to 9.

WO 99/36422

178

PCT/US99/00810


104. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 160:



Structure 160

wherein n is an integer of from 1 to 12 and R is -OCH₃ or -OCH₂Ph.


105. The compound of Claim 104 wherein n is an integer of from 3 to 10.
 106. The compound of Claim 104 wherein n is an integer of from 5 to 9.
 107. The compound of Claim 104 wherein n is an integer of from 6 to 9.
 108. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 162 :



Structure 162

wherein n is an integer of from 1 to 12 and R is -OCH₃ or -OCH₂Ph.


109. The compound of Claim 108 wherein n is an integer of from 3 to 10.
 110. The compound of Claim 108 wherein n is an integer of from 5 to 9.
 111. The compound of Claim 108 wherein n is an integer of from 6 to 9.
 112. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 164:



Structure 164

wherein n is an integer of from 1 to 12 and R is $-\text{OCH}_3$ or $-\text{OCH}_2\text{Ph}$.

- 113. The compound of Claim 112 wherein n is an integer of from 3 to 10.
- 114. The compound of Claim 112 wherein n is an integer of from 5 to 9.
- 115. The compound of Claim 112 wherein n is an integer of from 6 to 9.
- 116. The compound bacterial NAD synthetase inhibitor compound of Claim 2, having Structure 166:



Structure 166


wherein n is an integer of from 1 to 12 and R is $-\text{OCH}_3$ or $-\text{OCH}_2\text{Ph}$.

- 117. The compound of Claim 114 wherein n is an integer of from 3 to 10.
- 118. The compound of Claim 114 wherein n is an integer of from 5 to 9.
- 119. The compound of Claim 114 wherein n is an integer of from 6 to 9.
- 120. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 168:

WO 99/36422

180


PCT/US99/00810



Structure 168

wherein n is an integer of from 1 to 12 and R is -OCH₃ or -OCH₂Ph.

121. The compound of Claim 120 wherein n is an integer of from 3 to 10.
122. The compound of Claim 120 wherein n is an integer of from 5 to 9.
123. The compound of Claim 120 wherein n is an integer of from 6 to 9.
124. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 170:



Structure 170


wherein n is an integer of from 1 to 12 and R is -OCH₃ or -OCH₂Ph.

125. The compound of Claim 124 wherein n is an integer of from 3 to 10.
126. The compound of Claim 124 wherein n is an integer of from 5 to 9.
127. The compound of Claim 124 wherein n is an integer of from 6 to 9.
128. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 172:

WO 99/36422

181


PCT/US99/00810



Structure 172

wherein n is an integer of from 1 to 12 and R is $-OCH_3$ or $-OCH_2Ph$.


- 129. The compound of Claim 128 wherein n is an integer of from 3 to 10.
- 130. The compound of Claim 128 wherein n is an integer of from 5 to 9.
- 131. The compound of Claim 128 wherein n is an integer of from 6 to 9.
- 132. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 174:



Structure 174

wherein n is an integer of from 1 to 12 and R is $-OCH_3$ or $-OCH_2Ph$.


- 133. The compound of Claim 132 wherein n is an integer of from 3 to 10.
- 134. The compound of Claim 132 wherein n is an integer of from 5 to 9.
- 135. The compound of Claim 132 wherein n is an integer of from 6 to 9.
- 136. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 176:



Structure 176

wherein n is an integer of from 1 to 12 and Z is 3-quinoline, 3-(N,N-dimethylamino)phenyl, or 4-(N,N-dimethylamino)phenyl.

- 137. The compound of Claim 136 wherein n is an integer of from 3 to 10.
- 138. The compound of Claim 136 wherein n is an integer of from 5 to 9.
- 139. The compound of Claim 136 wherein n is an integer of from 6 to 9.
- 140. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 178:



Structure 178


wherein n is an integer of from 1 to 12.

- 141. The compound of Claim 140 wherein n is an integer of from 3 to 10.
- 142. The compound of Claim 140 wherein n is an integer of from 5 to 9.
- 143. The compound of Claim 140 wherein n is an integer of from 6 to 9.
- 144. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 180:

WO 99/36422

183


PCT/US99/00810



Structure 180

wherein n is an integer of from 1 to 12.

- 145. The compound of Claim 144 wherein n is an integer of from 3 to 10.
- 146. The compound of Claim 144 wherein n is an integer of from 5 to 9.
- 147. The compound of Claim 144 wherein n is an integer of from 6 to 9.
- 148. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 182:



Structure 182


wherein n is an integer of from 1 to 12.

- 149. The compound of Claim 148 wherein n is an integer of from 3 to 10.
- 150. The compound of Claim 148 wherein n is an integer of from 5 to 9.
- 151. The compound of Claim 148 wherein n is an integer of from 6 to 9.
- 152. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 184:

WO 99/36422

184


PCT/US99/00810



Structure 184

wherein n is an integer of from 1 to 12 and R is 6-CF₃, 5-OPh, 5-CH(CH₃)₂, 5-COCH₃ or 5-COPh.

- 153. The compound of Claim 152 wherein n is an integer of from 3 to 10.
- 154. The compound of Claim 152 wherein n is an integer of from 5 to 9.
- 155. The compound of Claim 152 wherein n is an integer of from 6 to 9.
- 156. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 186:



Structure 186

wherein n is an integer of from 1 to 12 and R is 6-CF₃, 5-OPh, 5-CH(CH₃)₂, 5-


WO 99/36422

185

PCT/US99/00810

COCH₃ or 5-COPh.


157. The compound of Claim 156 wherein n is an integer of from 3 to 10.
158. The compound of Claim 156 wherein n is an integer of from 5 to 9.
159. The compound of Claim 156 wherein n is an integer of from 6 to 9.
160. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 188:



Structure 188

wherein n is an integer of from 1 to 12 and R is 6-CF₃, 5-OPh, 5-CH(CH₃)₂, 5-COCH₃ or 5-COPh.


161. The compound of Claim 160 wherein n is an integer of from 3 to 10.
162. The compound of Claim 160 wherein n is an integer of from 5 to 9.
163. The compound of Claim 160 wherein n is an integer of from 6 to 9.
164. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 190:



Structure 190

wherein n is an integer of from 1 to 12 and R is 6- CF_3 , 5- OPh , 5- $\text{CH}(\text{CH}_3)_2$, 5- COCH_3 or 5- COPh .

165. The compound of Claim 164 wherein n is an integer of from 3 to 10.
166. The compound of Claim 164 wherein n is an integer of from 5 to 9.
167. The compound of Claim 164 wherein n is an integer of from 6 to 9.
168. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 192:



Structure 192


WO 99/36422

187

PCT/US99/00810

wherein n is an integer of from 1 to 12 and R is 6-CF₃, 5-OPh, 5-CH(CH₃)₂, 5-COCH₃ or 5-COPh.


169. The compound of Claim 168 wherein n is an integer of from 3 to 10.
170. The compound of Claim 168 wherein n is an integer of from 5 to 9.
171. The compound of Claim 168 wherein n is an integer of from 6 to 9.
172. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 194:



Structure 194

wherein n is an integer of from 1 to 12 and R¹ is an H or -OCH₂Ph and R² is H or COOCH₃.


173. The compound of Claim 172 wherein n is an integer of from 3 to 10.
174. The compound of Claim 172 wherein n is an integer of from 5 to 9.
175. The compound of Claim 172 wherein n is an integer of from 6 to 9.
176. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having



Structure 196

wherein n is an integer of from 1 to 12 and R^1 is H or $-OCH_2Ph$ and R^2 is H or $COOCH_3$.

177. The compound of Claim 176 wherein n is an integer of from 2 to 12.
178. The compound of Claim 176 wherein n is an integer of from 5 to 9.
179. The compound of Claim 176 wherein n is an integer of from 6 to 9.
180. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 198:



Structure 198


wherein n is an integer of from 1 to 12, and R^1 is H or $-OCH_2Ph$ and R^2 is H or $COOCH_3$.

WO 99/36422

189

PCT/US99/00810


181. The compound of Claim 180 wherein n is an integer of from 3 to 10.
182. The compound of Claim 180 wherein n is an integer of from 5 to 9.
183. The compound of Claim 180 wherein n is an integer of from 6 to 9.
184. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 200:



Structure 200

wherein n is an integer of from 1 to 12 and R¹ is H or a -OCH₂Ph and R² is H or COOCH₃.

185. The compound of Claim 184 wherein n is an integer of from 3 to 10.
186. The compound of Claim 184 wherein n is an integer of from 5 to 9.
187. The compound of Claim 184 wherein n is an integer of from 6 to 9.
188. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 202:



Structure 202


WO 99/36422

190

PCT/US99/00810

wherein R_1 is H or COOCH_3 .

189. The bacterial NAD synthetase enzyme inhibitor compound of Claim 2, having Structure 204:



Structure 204

wherein R_1 is H or COOCH_3 .

190. A method of treating or preventing a microbial infection in a mammal comprising administering to the mammal a treatment effective or treatment preventive amount of a bacterial NAD synthetase enzyme inhibitor compound.
191. The method of Claim 190 wherein the compound comprises a compound of Claim 1.
192. The method of Claim 190 wherein the compound comprises a compound of Claim 2.
193. The method of Claim 190 wherein the compound microbial infection is a bacterial infection.
194. The method of Claim 190 wherein the bacterium is a gram negative or gram positive bacteria.
195. The method of Claim 190 wherein the microbial infection comprises an infection caused by an antibiotic strain of bacteria.
196. The method of Claim 190 comprising oral, rectal, intramuscularly, intravenous, intravesicular or topical administration.

WO 99/36422

191

PCT/US99/00810

197. The method of Claim 190 wherein the compound is administered in a dosage of between about 0.1 to about 15g per day and wherein the dosage is administered from about 1 to about 4 times per day.
198. The method of Claim 190 further comprising administering a broad spectrum antibiotic.
199. A method of killing a prokaryote with an amount of prokaryotic NAD synthetase enzyme inhibitor to reduce or eliminate the production of NAD whereby the prokaryote is killed.
200. A method of decreasing prokaryotic growth, comprising contacting the prokaryote with an amount of a prokaryotic NAD synthetase enzyme inhibitor effective to reduce or eliminate the production of NAD whereby prokaryotic growth is decreased.
201. The method of Claim 199 wherein the inhibitor comprises a compound of Claim 1.
202. The method of Claim 199 wherein the prokaryote is a bacterium.
203. The method of Claim 202 wherein the bacterium is a gram negative or a gram positive bacteria.
204. The method of Claim 202 wherein the prokaryote is an antibiotic resistant strain of bacteria.
205. The method of Claim 202 wherein the NAD synthetase enzyme inhibitor is a compound that selectively binds with catalytic sites on a bacterial NAD synthetase enzyme to reduce or eliminate the production of NAD by the bacteria.
206. The method of Claim 202, wherein the NAD synthetase enzyme inhibitor is a compound that selectively binds with catalytic sites on a bacterial NAD synthetase enzyme to reduce or eliminate the production of NAD by the bacteria.
207. The method of Claim 199, wherein the administering step comprises oral, rectal, intramuscularly, intravenous, intravesicular or topical administration
208. The method of Claim 199 wherein the compound is administered in a dosage of between about 0.1 to about 15g per day and wherein the dosage is administered from about 1 to about 4 times per day.
209. The method of Claim 199 further comprising administering a broad spectrum antibiotic.

210. A disinfectant compound wherein the compound comprising a bacterial NAD synthetase enzyme inhibitor.
211. A method of disinfecting a material contaminated by a microbe, comprising contacting a contaminated material with a bacterial NAD synthetase enzyme inhibitor compound in an amount sufficient to kill or deactivate the microbe.
212. The method of Claim 211 wherein the compound comprises a compound of Claim 1.
213. The method of Claim 211 wherein the microbe is a bacterium.
214. A method of making a bacterial NAD synthetase inhibitor compound comprising the steps of:
 - a. alkylating 5-nitroindole with 6-bromohexyl acetate to form a 6-[*N*-(5-nitroindolyl)] hexyl acetate;
 - b. hydrolyzing the 6-[*N*-(5-nitroindolyl)] hexyl acetate to form *N*-(5-nitroindolyl)hexan-1-ol;
 - c. esterifying the 6-[*N*-(5-nitroindolyl)]hexan-1-ol with nicotinic acid to form *N*-(5-nitroindolyl)hexyl nicotinate; and
 - d. *N*-methylating the 6-[*N*-(5-nitroindolyl)]hexyl nicotinate.
215. A method of making a bacterial NAD synthetase inhibitor compound comprising the steps of:
 - a. alkylating 5-nitroindole with bromoalkyl acetate wherein the indole alkyl acetate is converted to indole alkyl alcohol;
 - b. reacting the indole alkyl alcohol with the appropriate reagent to form an indole alkyl ester; and
 - c. *N*-methylating the indole alkyl ester.
216. A method of making a bacterial NAD synthetase inhibitor compound comprising the steps of:
 - a. reacting indole carboxylic acid with the appropriate reagent to provide an indole carboxylate methyl ester or an indole benzyl carboxylate ester;
 - b. *N*-alkylating the indole carboxylate methyl ester or the indole carboxylate benzyl ester with bromoalkyl acetate;

- c. reacting the material from step b above with the appropriate reagent to form an indolealkyl alcohol;
 - d. coupling the indolealkyl alcohol with an aromatic amine; and
 - e. reacting the indolealkyl alcohol with the appropriate reagent to convert the methyl or benzyl indolecarboxylate to the respective indole carboxylic acids.
217. A method of making a bacterial NAD synthetase inhibitor compound comprising the steps of:
- a. brominating an aniline with N-bromosuccinimide to form a 2-bromo-R¹-substituted-aniline or a 2-bromo-R²-substituted-aniline;
 - b. reacting the 2-bromo-R¹-substituted-aniline or the 2-bromo-R²-substituted-aniline using a Heck coupling reaction to form an alkyne-substituted aniline;
 - c. reacting the alkyne-substituted aniline using a cyclization reaction to form an indole alcohol;
 - d. quaternizing the indole alcohol with an amine;
 - e. reacting the indole alcohol with methansulfonyl chloride to provide an indole mesylate; and
 - f. reacting the indole mesylate with a carboxylic acid to form an indole ester.
218. A method of making a bacterial NAD synthetase inhibitor compound comprising the steps of:
- a. brominating an aniline with N-bromosuccinimide to form a 2-bromo-R¹-substituted-aniline or a 2-bromo-R²-substituted-aniline;
 - b. reacting the 2-bromo-R¹-substituted-aniline or a 2-bromo-R²-substituted-aniline using a Heck coupling reaction to form an alkyne-substituted aniline;
 - c. reacting the alkyne-substituted aniline using a cyclization reaction to form an indole alcohol;
 - d. quaternizing the indole alcohol with an amine;
 - e. reacting the indole alcohol with trifluoromethylsulfonic anhydride to provide a triflate; and
 - f. reacting the indole triflate with an amine to form an indole alkylammonium product.

WO 99/36422

194

PCT/US99/00810

219. A method of generating a library comprising at least one bacterial NAD synthetase enzyme inhibitor compound comprising the steps of:
- g. obtaining the crystal structure of a bacterial NAD synthetase enzyme;
 - h. identifying one or more sites of catalytic activity on the NAD synthetase enzyme;
 - i. identifying the chemical structure of the catalytic sites on the NAD synthetase enzyme;
 - j. selecting one or more active molecules that will demonstrate affinity for at least one of the catalytic sites on the NAD synthetase enzyme;
 - k. synthesizing one or more dimeric compounds comprised of at least one active molecule compound wherein the active molecule compound are joined by means of n linker compounds and wherein n is an integer of from 1 to 12, and
 - l. screening the one or more compounds for bacterial NAD synthetase inhibitor activity.
220. The method of Claim 219 wherein the library comprises one or more compounds of Claim 1.
221. The method of Claim 219 wherein the library comprises one or more compounds of Claim 2.
222. The method of Claim 219 comprising at least two active molecule compounds.
223. The method of Claim 219 wherein the active molecules are the same.
224. The method of Claim 219 wherein the active molecules are different.
225. The method of Claim 219 wherein a software program that predicts the binding affinities of molecules to proteins is utilized in the active molecule selection step.
226. The method of Claim 219 wherein a software program that evaluates the chemical and geometric complementarity between a small molecule and macromolecular binding site is utilized in the active molecule selection step.
227. The method of Claim 219 wherein the compounds are synthesized utilizing a rapid, solution phase parallel synthesis and wherein the compounds are generated in a combinatorial fashion.
228. A method for the *in vitro* screening a compound for bacterial NAD synthetase enzyme inhibitory activity comprising the steps of :

WO 99/36422

195

PCT/US99/00810

- a. preparing a bacterial NAD synthetase enzyme solution from pure bacterial NAD synthetase enzyme mixed with a suitable buffer;
- b. contacting the bacterial NAD synthetase enzyme solution with a test compound; and
- c. measuring the rate of the enzyme-catalyzed reaction between the NAD synthetase enzyme and the test compound,

wherein the rate of the enzyme catalyzed reaction comprises a measure of bacterial NAD synthetase enzyme inhibitory activity.

229. The method of Claim 228 wherein the rate of the enzyme catalyzed reaction comprises a measure of the antibacterial properties of the test compound.
230. The method of Claim 228 wherein the rate of the enzyme catalyzed reaction comprises a measure of the antimicrobial properties of the test compound.
231. The method of Claim 228 wherein the bacterial NAD synthetase enzyme comprises a gram positive bacteria, a gram negative bacteria or a combination thereof.
232. The method of Claim 228 wherein the assay volume is about 2.0 mL.
233. The method of Claim 228 wherein the assay volume is about 0.2 ml.
234. The method of Claim 228 wherein the test compound is applied in an amount of greater than about 500 μ L.
235. The method of Claim 228 wherein the test compound is applied in an amount of greater than or equal to about 200 μ L.
236. The method of Claim 228 wherein the test compound is applied in an amount of equal to or less than about 200 μ L.

INTERNATIONAL SEARCH REPORT

Int. National Application No.

PCT/US 99/00810

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D401/12 A61K31/40 A01N43/38 C07D401/06 C07D209/08
 C07D209/12 C07D209/42 C07D213/80

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K A01N G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 289 777 A (RUDOLF ALBRECHT ET AL.) 15 September 1981 see column 6; claim 1 ---	1
A	EP 0 585 722 A (EISAI CO., LTD.) 9 March 1994 see claims -----	1

☐ Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

19 April 1999

Date of mailing of the international search report

27/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Van Bijlen, H

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/00810

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 190-209
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 190-209
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/00810

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4289777	A	15-09-1981	DE 2856908 A	17-07-1980
			AT 1777 T	15-11-1982
			DK 551179 A,B,	29-06-1980
			EP 0012925 A	09-07-1980
			GB 2044253 A	15-10-1980
			IE 49498 B	16-10-1985
			JP 1000951 B	10-01-1989
			JP 1517412 C	07-09-1989
EP 585722	A	09-03-1994	JP 55092372 A	12-07-1980
			AT 137969 T	15-06-1996
			CA 2104531 A	22-02-1994
			DE 69302646 D	20-06-1996
			DE 69302646 T	31-10-1996
			DK 585722 T	05-08-1996
			ES 2087623 T	16-07-1996
			FI 933681 A	22-02-1994
			GR 3019917 T	31-08-1996
			JP 2798588 B	17-09-1998
			JP 7069888 A	14-03-1995
			NO 932947 A	22-02-1994